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Abstract 
Schizophrenia, aging, and medication factors combine to present a very complex clinical 
presentation in caring for the elderly population with schizophrenia. The aging body 
displays a slowing of physiological processes, which alters the pharmacokinetics and 
pharmacodynamics of medications prescribed.  Multiple comorbid health factors and the 
medications recommended for treatment may become detrimental to the overall body 
health, causing more problems for the older individual.  This evidence based practice 
project reviewed literature and evidence to focus on the question, “In community 
dwelling older adults with schizophrenia, what is best practice for antipsychotic 
medication management?”  The literature search resulted in classifying 16 articles as 
relevant to medication management in older adults with schizophrenia. The results of this 
project were limited by the paucity of available quality research material on the subject.  
Few studies were inclusive of the 65-years and older population.  However, the literature 
analysis resulted in several recommendations to guide decision-making and promote the 
safe incorporation of antipsychotic medications in the plan of care to treat schizophrenia 
in older patients.  These may be used by Psychiatric-Mental Health Nurse Practitioners in 
the clinical reasoning process. 
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Chapter 1   Introduction 
Schizophrenia is on the rise among the elderly in the United States.  The 
prevalence of schizophrenia in people age 65 and over is 0.5% of the total population 
(Reeves et al., 2011).  With the impact of medical advances through research, life 
expectancy is projected to continue its upward trend (“Explaining divergent,” 2011). This 
results in the population of elderly schizophrenic patients doubling over the next two 
decades. Mental health practitioners will be caring for the greater proportion of these 
older patients in mental health clinics. Preparations are necessary to plan for the best care 
focusing on this special population and their unique needs.   
Schizophrenia is a chronic mental health problem characterized by a mixture of 
positive and negative symptoms.  Positive symptoms include excess or distortions of 
thought content, perception, language, thought processing, and self-monitoring.  Negative 
symptoms are restrictions in range and intensity of emotion, fluency and productivity of 
thought and speech, and initiation of goal-directed behavior.  For the diagnosis to be 
made these symptoms must be present for the majority of one month or some persisting 
symptoms should be present at least six months. These symptoms are associated with 
marked social or occupational dysfunction as well as a range of cognitive, emotional and 
communication dysfunction (“Schizophrenia,” n.d.).  Schizophrenia is usually diagnosed  
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between the ages of 10 to 25 years for men and 25 to 35 years for women (Sadock & 
Sadock, 2007).  These individuals can expect a lifetime of challenges including unmet 
health care needs, lessened quality of life and higher mortality rates (Saha, Chant, & 
McGrath, 2007). 
As with the general population, the number of older adults with schizophrenia is 
increasing. Currently there are 2.2 million Americans suffering from schizophrenia 
(Reeves et al., 2011).  The disease and aging factors combine to present a very complex 
situation for the context of care and action and side effects of drugs. The clinical picture 
is confounded by multiple medical comorbidities, physiological changes of aging, 
polypharmacy issues, and alcohol and substance abuse. This chapter examines these 
factors, describes the synergy among them complicating medication management, and 
presents the evidence-based practice (EBP) question with definitions.  This evidence-
based project’s focus is safe and effective medication management for the aging 
population with schizophrenia.  
Background and Significance 
The core symptoms of schizophrenia arise from dysfunction in many areas of the 
brain.  Effective treatment involves targeted medication therapy aimed at the specific 
areas of the brain involved.  Timely treatment may prevent or delay the full-syndrome 
onset of schizophrenia (Miller, 2009).  Studies of schizophrenia in the elderly population 
suggest that consistency of treatment and medication are a predictor of successful 
symptom management (Sapra, Vahia, Reyes, Ramirez, & Cohen, 2008; Farley, Wang, 
Hansen, Voils, & Maciejewski, 2011).  Currently clinicians are aware that older adults 
with schizophrenia have complicated management issues because of the multiple levels 
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of medication necessary to care for the spectrum of health needs including both mental 
and physiological illnesses commonly associated with aging.  Unless a best practice 
approach is used, this predicted load on the mental health system into the next decade 
will result in more adverse physical health problems. 
Context of Care  
A majority of the elderly population with schizophrenia today dually is eligible to 
receive both Medicare and Medicaid.  Medicare has been further divided into Part A 
(hospital insurance coverage), Part B (medical provider insurance coverage), and Part D 
(prescription drug coverage). Medicare Part D is available from multiple insurance 
companies that offer a variety of coverage dependent on patient preference.  Medicaid is 
a jointly funded state and federal funding health care for low income and disabled 
individuals (“Eligibility,” n.d.). Appropriate medication management is made more 
difficult within the government systems because of fragmented mental health care, fewer 
trained providers, complicated and restrictive insurance management, decreasing funding, 
and increased caseloads.   
Fragmentation of care. Due to shortages in the community of health care 
professionals trained to provide safe and effective care for older people with 
schizophrenia, medical problems often go unnoticed or are misdiagnosed (Bartels, 2004).   
It is estimated that one half of this population have co-occurring medical and substance 
abuse disorders, and almost half of these disorders are either not diagnosed or are 
inappropriately treated (Rosenberg, Woo, & Roane, 2009).  Medical clinics are not 
equipped to manage the care of patients with chronic severe mental illnesses because of 
the complexities of psychiatric issues.  Mental health clinics only focus on the psychiatric 
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issues. Additionally, physical illnesses and early signs of physical or emotional problems 
are often incorrectly assumed to be part of the delusional symptoms of the mental illness 
(Csernansky, 2002).  This misdiagnosis delays the onset of effective treatment, which 
may in turn lead to severe or life-threatening conditions.  Dementia symptoms may also 
be misinterpreted as a part of the psychiatric presentation resulting in inappropriately 
prescribed or adjusted medications (Csernansky, 2002).  This fragmentation of care is 
only one pressing concern. 
 Fewer trained providers. Most elderly patients with schizophrenia receive the 
majority of their psychiatric care from local mental health centers in the community.  As 
funding cuts occur in each state, the amount of money supporting mental health treatment 
has decreased.  Funding for schools with mental health nurse practitioner curricula has 
also decreased, resulting in the closure or suspension of many programs and declining 
numbers of providers entering the workforce. This lack of support leaves fewer trained 
providers with specialization in mental health to staff the community centers to care for 
the needs of the population with schizophrenia.  Patients also often lack support to 
navigate the insurance system. 
Complicated and restrictive insurance. The healthcare system makes acquiring 
the necessary medication complicated for the provider as well as the elderly patient with 
schizophrenia.  Medicare insurance has a limited formulary and protocol that must be 
followed by prescribers that still may result in denial or less than full coverage for 
antipsychotic medications.  When the newest medications gain Food and Drug 
Administration (FDA) approval, the co-pay often results in a higher level of coverage 
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requiring more personal outlay of money.  Although these drugs may be better tolerated 
with fewer side effects, thereby desired for this patient population, the cost is prohibitive.   
Even if Medicare approves a drug, acquiring the medication is still fraught with 
additional system problems.  Quantities of prescribed medications could be limited to 30 
pills a month making a preferred multiple dosing per day protocol problematic.  
Recommendations made to prescribers by the insurance company for alternative choices 
of drugs, or tiers, are often not suitable for the elderly patient with schizophrenia because 
of negative side effects.  Practitioners may be directed to follow step therapy requiring 
the patients documented history of failed attempts on other drugs preferred by the 
insurance company to be filed in a lengthy review.  This process takes precious time 
away from patient care and delays the introduction of needed medication that will 
alleviate suffering and eliminate symptoms.   
Economic challenges. A monthly Supplemental Security Income (SSI) check, 
intended to support a base subsistence, is provided to the elderly person with 
schizophrenia at age 65 years old or prior if disability was determined.  The average SSI 
monthly check in 2013 was $423.02 with 2,092,000 recipients.  Of this group, 919,000 
received this SSI as their only support (“Monthly statistical,” 2013).  This meager amount 
must be used to pay for all supplemental costs of healthcare as well as living expenses.  
Following up with all providers and paying Medicare Part D costs for drug coverage both 
pose additional financial strain on already tight budgets.    
Additionally, many provider practices want co-payment for service. This is not 
easily affordable to a population also struggling to pay for medications prescribed for 
treatment.  With multiple providers, the costs can be compounded by each specialist 
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attending to the needs of the elderly patient with schizophrenia.  Once Medicare Part D 
has paid for a preset maximum amount, the patient must pay “out of pocket” until a 
maximum amount is paid which is sometimes thousands of dollars. This is referred to as 
the “donut hole” of coverage. The Affordable Care Act (ACA) is scheduled to gradually 
reduce the amount of co-payment and percentage of “out of pocket” expense through 
2020.  In 2013, the ACA offered the elderly a 52.5% discount on name brand drugs and a 
21% discount for generic drugs (Kaplan, 2011).  Incremental decreases over the next 
seven years will be small and slow leading to an end point of 25% responsibility for both 
generic and name brand name drugs in 2020 and a $903 annual cost as the enrollee’s 
responsibility (Kaplan, 2011). 
Alternative options for patients to acquire the necessary medication for treatment 
of schizophrenia are few, despite the potential risks to self and others when individuals 
receive inadequate treatment.  The patient must rely on samples or patient assistance 
programs designed by the drug companies to assist during this “donut hole” of coverage. 
With the increased cost, elderly patients with schizophrenia often economize by taking 
the medication less often than ordered or not filling the prescription.  This irregular or 
absent dose may lead to decompensation with psychosis, instability, and potential harm to 
these elderly patients. Utilization of emergency services, admissions to acute care 
hospitals, and interventions resulting from this destabilization further increase the cost of 
mental health.  Cost concerns are also often compounded with the issue of limited 
providers. 
Limited providers. Methods used to manage resources include limiting 
reimbursements to providers for services and placing restrictions on prescribing practices 
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for medications. The percentage of Medicare patients per practice is capped in many 
offices to buffer the overall decreased repayment for care paid by this plan.  This reduced 
Medicare reimbursement provides a disincentive for providers to accept new geriatric 
patients (Rosenberg et al., 2009).  These issues, along with the lack of knowledgeable 
providers willing to negotiate and maintain both the medical and psychiatric needs of this 
elderly population, are some of the flaws of the healthcare system that severely impact 
the care options of the elderly population with schizophrenia.  Having examined the 
complicated context in which elderly patients with schizophrenia seek care, the actions 
and side effects of psychopharmacology follows. 
Actions and Side Effects of Drugs 
 Just as the health care context is complex, so too are the action and side effects of 
antipsychotic drugs.  Psychopharmacological intervention involves modulation of 
multiple neurotransmitters aimed at a remission of symptoms of schizophrenia. These 
antipsychotic drugs are known to be “the most complex pharmacological mechanisms of 
any drug class in the field” (Stahl, 2008, p. 328).  Prescribing practice for the older 
population with schizophrenia is focused on identifying the specific neural pathways of 
the brain to target treatment for optimum symptom management with minimum side 
effect potential.  Table 1.1 reviews the major neural pathways affected by the most 
commonly prescribed antipsychotic in each class of medications prescribed for the older 
population with schizophrenia.  
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Table 1.1  
 
Neural Pathways and Side Effects of Antipsychotic Drug Classes 
 
Drugs by Class Neural Pathways Effected Common Side Effects 
• Alpha – 1  • Dizziness, drowsiness, and 
decreased blood pressure. 
• Dopamine- (D2 antagonist) • Apathy, lack of motivation, 
anhedonic, movement disorders, 
and elevated prolactin 
(galactorrhea, amenorrhea, 
demineralization of bones, weight 
gain). 
• Histamine (H1) • Weight gain, drowsiness. 
• Typical 
(Conventional) 
• Muscarinic (M1) • Constipation, blurred vision, dry 
mouth, and drowsiness. 
      
• Atypical • Serotonin Dopamine 
Antagonists*                           
• D2 antagonists with rapid 
disassociation*        
• Serotonin -Dopamine Partial 
Agonist*                      
• Serotonin partial agonist at 
5HT1A receptor* 
• Weight gain                                 
• Dyslipidemia                              
• Diabetic risks                              
• Anxiety                                       
• Prolonged QT interval                
• Elevated prolactin levels            
• EPS                                             
• Sedation 
Note. Adapted from Stahl’s essential psychopharmacology: Neuroscientific basis and 
practical applications (3rd ed.), by S. M. Stahl, 2008, p. 342.  
* The pharmacologic methods that serotonin and dopamine interact within the D2 
receptor to elicit the desired antipsychotic effect are found in these four types of agonist. 
They are unique to the atypical psychodynamic profile.  
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Schizophrenia is a disorder affecting many areas of functioning including 
cognitive, affective, negative, positive, and aggressive symptoms (see Figure 1.1).  It is 
difficult to envision one medication effectively treating all these areas (Stahl, 2008). The 
five-dopamine pathways and symptoms associated with each are illustrated in Figure 1.1.   
 
 
Figure 1.1 Schizophrenia model of dopamine output.  Adapted from Stahl’s essential 
psychopharmacology: Neuroscientific basis and practical applications (3rd ed.) by S.M. 
Stahl, 2008, p. 262.   
 
  
10 
Antipsychotic medications are responsible for a higher risk potential of major side 
effects in the elderly population with schizophrenia.  The cause of side effects in some 
cases is known, as in the case of movement disorders associated with dopamine 
antagonism in the nigrostriatal dopamine track (Leon et al., 2010).  However, for some 
side effects the cause is not known.  These include causes of neuroleptic malignant 
syndrome (NMS) as well as sudden cardiac death and strokes (Novick, Haro, Bertsch & 
Haddad, 2010).  Table 1.2 highlights the movement disorders and symptoms of each. 
Movement disorders, also called pseudo-Parkinsonian symptoms, can be 
classified in two types: extrapyramidal symptoms (EPS) and tardive dyskinesia (TD).  
EPS includes a variety of symptoms characterized by changes in muscle tone, poverty of 
voluntary movements (akinesia) or abnormal involuntary movements (dyskinesia).  EPS 
is associated with both conventional (typical) and atypical antipsychotic medication 
administration.  Symptoms may be acute or chronic, or delayed as in TD.   Their presence 
may spontaneously resolve or be permanent.  
Tardive dyskinesia is a disorder of involuntary repetitive body movements that 
can be delayed or slow in onset, which appears after high dose use of antipsychotics 
(Lieberman & Tasman, 2006).   Aging of the brain decreases dopamine functioning in the 
corticostriatal pathway causing an increased prevalence of both extrapyramidal  
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Table 1.2  
Antipsychotic Drug Side Effects 
Name Category Symptoms 
• Extrapyramidal Symptoms  • Change in muscle tone, 
poverty of voluntary 
movements (akinesia), 
abnormal involuntary 
movements (dyskinesia) 
• Movement Disorders 
• Tardive Dyskinesia • Involuntary repetitive body 
movements: Grimacing, 
tongue protrusion & 
movements, lip smacking, 
puckering or protrusion, rapid 
eye blinking, grunting, tics 
and/or movements of limbs, 
torso, or fingers. 
• Neuroleptic 
Malignant Syndrome 
• Neurological • Life threatening disorder: 
Rigidity, autonomic 
instability, altered level of 
consciousness and 
hyperthermia, elevated 
creatine, kinase, and 
leukocytosis 
 
Note. Adapted from “Incidence of extrapyramidal symptoms and tardive dyskinesia in 
schizophrenia” by D. Novick, J. Haro, J. Bertsch, and P. Haddad, 2010, Journal of 
Clinical Psychopharmacology, 30(5), pp. 531-540.  
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symptoms and tardive dyskinesia (Meyers & Jeste, 2010). As a result, TD and EPS 
symptoms may also occur with lower doses and can be more persistent and severe (Leon 
et al., 2010).   
 Neuroleptic malignant syndrome (NMS) is a life-threatening neurological 
disorder associated with antipsychotic medications.   Symptoms of NMS are rigidity, 
autonomic instability, altered level of consciousness, hyperthermia, and elevation of 
creatine kinase and leukocytosis (Lieberman & Tasman, 2006).  The onset can be sudden, 
occurring usually in the early course of the medications. Understanding the potential risk 
and recognizing these possibly life-threatening syndromes is critical to safely prescribing 
antipsychotic medications to this older population with schizophrenia (Novick et al., 
2010). 
General side effects of antipsychotic medications are varied and unique, as one 
individual’s response to treatment may be quite different from another’s response to the 
same medication.  Some antipsychotics trend towards common side effects in a larger 
portion of the population treated with the medication. Sedation is a common side effect of 
specific medications and can be better tolerated with a bedtime dosing pattern. While 
providing symptom relief of schizophrenia, practitioners need to be aware of the potential 
of side effects to provide optimum care as safely as possible.  
Table 1.3 reviews the major medications used in the treatment of schizophrenia 
with information about metabolism, classification, dosing, excretion, peak level of drug 
concentration (C-Max), half-life, protein binding, and special considerations for the older 
adult population with schizophrenia.  
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Table 1.3  
Medication Data 
Drug Name Available 
Route/Dosing  
Half-
Life 
Peak 
Concentration 
(Cmax) 
Absorption & 
Excretion 
Absorption Issues 
and Special Notes 
Serotonin-dopamine antagonist — SDA/SGA 
Brand: 
Zyprexa                                                
(Generic is 
Olanzapine) 
Oral daily 
dosing
21 to 
54 
hours  
5 hours 85% GI / 40% 
inactivated by 
first pass 
hepatic 
metabolism. 
Excreted 57% 
renal, 30% by 
GI.  Protein 
binding 93%. 
No absorption 
issues with food. 
Luvox and 
tagamet 
increases serum 
carbamazepine 
and decreases 
phenytoin levels. 
Alcohol 
increases 
absorption by 
25%. 
Brand: 
Relprevv                                               
(Generic is 
Olanzapine) 
IM (Depot) 
administer
every 2 to 4 
weeks. 
30 
days 
14-45 min Absorption 
rapid. (IM) 
Post injection 
delirium 
sedation 
syndrome 
(PDSS) potential 
— must be 
observed for 3 
hours after IM. 
Brand: 
Seroquel 
(Generic is 
Quetiapine) 
Oral 
(regular       
2 times a 
day dosing) 
7 
hours 
1-2 hours Rapidly 
absorbed from 
GI/ Excretion 
73% renal, 
20% GI. 
Protein binding 
83%. 
Marginal effect 
with food. 
Phenytoin 
increased 
clearance 5 
times normal. 
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Brand: 
Seroquel XR 
Oral 
(delayed 
release, 
daily dosing 
3-4 hrs. 
prior to 
sleep)  
9-12 
hrs. 
6 hours Rapidly 
absorbed from 
GI/ Excretion 
73% renal, 
20% GI. 
Protein binding 
83%. 
Absorption 
slowed with high 
fat foods (22-
52%) 
Brand:  
Geodon 
(Generic is 
Ziprasidone) 
Oral (2 
times daily 
dosing 
recmd.) 
5-10 
hrs. 
2-6 hours Bioavailability 
doubles when 
taken with 
food (300 cal) 
-absorption 
rapid. 
Excretion 20% 
renal, 66% GI. 
Protein binding 
< 99% 
Interactions with 
other drugs that 
prolong QT 
intervals. 
Brand:   
Invega 
(Generic is 
Paliperidone) 
Oral (daily 
dosing) 
4-5 
days 
24 hours Bioavailability 
28%. 74% 
protein 
binding. 
Limited 
hepatic 
metabolism. 
Excretion 11% 
GI, renal 80%.  
Protein binding 
74% 
With or without 
food.  Reduce 
dose in renal 
impairment. 
Avoid with other 
drugs that 
prolong QT. 
Brand:     
Invega 
Sustenna 
(Generic is 
Paliperidone 
palmitate) 
Depo (every 
4 weeks) 
25-49 
days 
1 day Bioavailability 
28%. 74% 
protein 
binding. 
Limited 
hepatic 
metabolism. 
Excretion 11% 
GI, renal 80%. 
2 initial doses 
required. #1- in 
deltoid (28% 
higher 
absorption), 
#2.5-7 days later 
in muscle of 
choice. 
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Brand: 
Risperdal 
(Generic is 
Risperidone) 
Oral (daily 
dosing) 
Up to 
17 
hours 
1-3 hours Bioavailability 
70% 
Excretion: 
70% renal, 
14% GI. 
Protein binding 
90% 
May inhibit 
active metabolite 
when used with 
strong SSRIs 
and elevate 
prolactin level. 
Brand:  
Risperdal 
Consta 
Depo - IM 
(every 2 
weeks) 
3-6 
days 
3 weeks Bioavailability 
70% 
Excretion: 
70% renal, 
14% GI. 
Protein binding 
90% 
Requires 3 doses 
to reach steady 
state (6 weeks). 
Supplement with 
oral medication 
until after 3rd 
dose.  
Brand: 
Clozaril 
(Generic is 
Clozapine) 
1 to 2 times 
a day 
12 
hours 
2 hours Bioavailability 
50-60%.  
Excreted 30% 
GI, 50% renal. 
Protein binding 
97%. 
Unaffected by 
food 
Brand:   
Fanapt 
(Generic is 
Iloperidone) 
Oral (2 
times a day 
dosing) 
(1) 
18-26 
hrs. 
(2) 
31-37 
hrs.  
2 - 4 hours Hepatic 
metabolism 
excretion. 
Protein binding 
- 95%.  
Excreted via 
renal -58-45%  
and 20-22% GI 
1) CYP 2D6 
extensive 
metabolizers,   
2) CYP 2D6 
poor 
metabolizers. 
Dose adjustment 
needed. No 
interaction with 
food. 
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Brand:   
Latuda 
(Generic is 
Lurasidone) 
Oral (daily 
dosing) 
18 
hours 
1-3 hours Renal and GI 
excretion. 
Protein binding 
– 99% 
Should be taken 
with food (350 
cal). Without 
food absorption 
impaired. 
Grapefruit 
products should 
be avoided. 
Brand: 
Abilify 
(Generic is 
Aripiprazole) 
Oral (daily 
dosing) 
75 
hours 
3-5 hours Readily 
absorbed. 
Excretion 25% 
renal, 55% GI.  
Protein binding 
<99%.  Steady 
state achieved 
in 14 days. 
Absorption 
unaffected by 
food. 99% 
protein bound.  
Clearance 
reduced in 
elderly. 
Modulates 
dopamine rather 
than blocks. 
Parent 
compound is the 
aripiprazole, 
major 
metabolite, 
dehydro- 
aripiprazole may 
take longer ½ 
life (94 hrs.) 
Brand: 
Abilify 
Maintena 
(Generic is 
Aripiprazole) 
Depo- IM 29.9 
days 
5-7 days Hepatic 
excretion. 
Steady state  
achieved after 
4 injections. 
29% protein 
bound. 
Not tested or 
recommended in 
65 years or 
older. 
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Brand:  
Saphris 
(Generic is 
Asenapine) 
Sublingual 
(2 times a 
day) 
24 
hours 
1 hour Protein binding 
95%. 
Bioavailability 
35%. 
Extensive 
hepatic 
metabolism. 
Excretion- 
40% GI, renal 
50%. 
No food or 
liquid for 10 
min. Caution 
with Luvox. 
Drug Name Available 
Route/Dosing  
Half-
Life 
Peak 
Concentration 
(Cmax) 
Absorption & 
Excretion 
Absorption Issues 
and Special Notes 
Dopamine Receptor Antagonist- DRA/FGA 
Brand: 
Haldol 
(Generic is 
Haloperidol) 
Oral 10 to 
37 
hours 
20 minutes Protein bound 
90%   
Bioavailability 
60-70% 33-
40% renal 
excretion, 15% 
GI.  High 
potency 
Well absorbed 
from GI tract.  
Smoking, coffee, 
antacids and 
food interfere. 
Clearance 
inhibited by 
SSRIs, TCAs, 
cimetidine, beta-
blockers, 
isoniazid, 
methylphenidate, 
erythromycin, 
triazolo-
benzodiazepines, 
ciprofloxacin, 
and 
ketoconazole. 
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Brand: 
Haldol 
Decanoate 
Depot, IM  3 wks 2-6 hours Peak 
concentration 6 
days 
Smoking, coffee, 
antacids and 
food interfere 
with absorption. 
Clearance 
inhibited by 
SSRIs, TCAs, 
cimetidine, beta-
blockers, 
isoniazid, 
methylphenidate, 
erythromycin, 
triazolo-
benzodiazepines, 
ciprofloxacin, 
and 
ketoconazole. 
Brand: 
Trilafon 
(Generic is 
Perphernazine) 
Oral (2-4 
times a day 
dosing)   
9-12 
hrs. 
1-3 hours Bioavailability 
20%. 
Metabolism in 
liver, GI tract. 
Protein binding 
90%. Medium 
potency. 
2-3 weeks for 
desired results. 
Lithium 
formulation may 
decrease serum 
concentration of 
antipsychotic. 
Brand: 
Thorazine 
(Generic is 
Chlorpromazine 
hydrochloride) 
Oral (2-4  
times a day 
dosing) 
6 
hours 
2.8 hours Bioavailability 
32%. Protein 
binding 90-
99%. Low 
potency. 
May cause 
gynecomastia, 
hyper- or hypo 
glycemia. 
Brand: 
Prolixin 
(Generic is 
Fluphenazine) 
(1-2 times 
daily 
dosing) 
33 
hours 
1-4 hours Bioavailability 
2.7%. 
Metabolized via 
hepatic system. 
Protein binding 
90%. High 
potency. 
Report CNS 
effects (blurred 
vision, altered 
gait, excess 
sedation urinary 
retention) 
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Brand: 
Prolixin 
Decanoate 
Depo, IM 
(every 2-4 
weeks) 
6.8-
9.6 
days 
48-96 
hours 
Bioavailability 
2.7%. 
Metabolized 
via hepatic 
system. Protein 
binding 90%. 
High Potency. 
IM response 
may last up to 6 
weeks. 
Brand: 
Stelazine 
(Generic is 
Trifluoperazine) 
1-2 times a 
day dosing 
24 
hours 
2-4 hours Bioavailability 
readily 
available. 
Metabolism 
via hepatic. 
Protein binding 
>90%. 
Medium 
Potency. 
Lower dose with 
more gradual 
increase for 
elderly. 
Note.  Adapted from Physicians’ Desk Reference (67th ed.) by E. Strompf, 2012. 
Copyright 2013 by PDR Network. 
Definitions for Table 1.3 
Atypical antipsychotic medications: synonymous with second-generation 
antipsychotic medications (SGA). 
Bioavailability: The fraction of the total amount of administered medication that 
can be recovered from the bloodstream for use by the target tissue. 
Half-life: The amount of time it takes for metabolism and excretion to reduce the 
particular plasma concentration by 50%.  
First-pass metabolism: The initial metabolism of orally administered medications 
within the portal circulation of the liver referring to the fraction of absorbed drug 
reaching the systemic circulation unmetabolized. 
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Metabolism: The liver being the principle site of drug metabolism, with feces, bile 
and urine being the major routes of excretion. Antipsychotic drugs are also excreted in 
saliva, sweat, tears and breast milk. 
Protein binding: Percentage of drug bound to a protein molecule (albumin, 
lipoprotein, glycoprotein, and globulins). Unbound portion of drug is readily metabolized 
and or excreted whereas bound portion has higher half-life and slower release. 
Potency: The amount of drug required for the drugs’ specific effect to occur. 
Peak concentration (C-max): The maximum concentration a drug achieves prior 
to a second dosing and a point to which short-term side effects are more likely to occur. 
Neuroleptic medication: Synonymous with antipsychotic medication both typical 
and atypical factors. 
Typical Antipsychotic medications: Synonymous with first generation 
antipsychotic medications (FGA)  
 
In Table 1.3, the drug classes are grouped according to drug classes, listed as the effect 
the medication has on the dopamine receptors in the brain.  Further examination of 
antipsychotic medications will continue in Chapter 2, as the effects of antipsychotic 
medications by body systems will be examined in detail.  Before moving on, it is 
essential to take into consideration the many confounding factors of pharmacology. 
Confounding Factors of Pharmacology 
Medical comorbidities, physiologic changes of aging, polypharmacy, and alcohol 
abuse, are common in the elderly patient.  These concerns place older individuals with 
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schizophrenia at elevated risk for adverse drug reactions from medication prescribed to 
control symptoms.  With the complexity of multiple issues co-occurring, the problems 
increase for safe prescribing.  Awareness of these issues is essential. 
Medical Comorbidities   
Long-term use of atypical antipsychotic medication is associated with a cluster of 
related risk factors.  Coronary heart disease had a significant increase over a 10 year span 
of study for middle age and older adult schizophrenia patients (Jin et al., 2011).  
Metabolic syndrome (MetS), which, when co-occurring with other disorders, increases an 
individual’s risk of developing cardiovascular disease and insulin resistance leading to 
various diabetic states and cardiovascular disease in adults was also a concern (Kisely, 
Cox, Campbell, Cooke, & Gardner, 2009). Patients with schizophrenia had a higher 
incidence of diabetes for the youngest adult age group when compared to the general 
population (Hsu, Chien, Lin, Chou, & Chou, 2011).  In a meta-analysis representing 48 
studies of adults, clozapine and olanzapine had the highest risk of producing metabolic 
issues including weight gain, altered glucose metabolism, and elevated triglycerides 
within the class of atypical antipsychotics (Rummel-Kluge et al., 2010).  The general 
features of metabolic syndrome include elevated blood pressure, atherogenic 
dyslipidemia, insulin resistance, and abnormal body fat distribution (Alberti, Zimmet, & 
Shaw, 2006).   
Other factors contributing to MetS include physical inactivity, aging, 
proinflammatory state, hormonal dysregulation, and genetic predisposition (Alberti et al., 
2006). A high fat carbohydrate rich diet often associated with limited income also 
increases the risk for MetS.  Hyperlipidemia, obesity, and nicotine abuse contribute to 
  
22 
medical comorbid health issues as well by further compounding the problems with 
respiratory, musculoskeletal, and peripheral vascular issues.    
Physiological Changes of Aging 
Patients with schizophrenia often have metabolic issues that cause aging changes 
to occur earlier than in the population without schizophrenia.  Premature intracellular 
deterioration in the older adult with schizophrenia precedes many metabolic health issues 
(Jeste, Wolkowitz, & Palmer, 2011). The origin of this premature aging remains 
debatable.  There are several theories that try to explain this event. The first theory 
outlines a course of declining health secondary to the cumulative systemic effects of 
psychotropic medication. A second theory examines the contributing effect of the 
inflammatory response with oxidative stress as a focal point.  This response increases C-
reactive protein, cortisol, insulin, and suppresses certain anabolic hormones.  Individuals 
with schizophrenia were found to have increased T-cell activity (pro-inflammatory 
activation), which is upregulated in acute inflammatory process, metabolic, and 
cardiovascular disease (Suvisaari et al., 2011).  These biochemical reactions create the 
perfect environment for deterioration of the telomerase that is the protective cap at the 
end of the DNA chain.  Results of this loss link diabetes, insulin resistance, higher 
cardiovascular disease, obesity, hypertension, and dyslipidemia to schizophrenia (Epel, 
2009).  
Early aging problems in the elderly brain associated with schizophrenia also cause 
unique and confusing neurocognitive changes.  Decreasing gray matter volumes in the 
frontal and parietal lobes occur in the aging brain with schizophrenia (Jeste et al., 2011). 
This cognitive change decreases the older adults’ ability to live alone and work 
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successfully within healthy boundaries of self-care. Recognition of key medical issues 
may also be diminished by the cognitive deficits of schizophrenia (Karim, Overshott, & 
Burns, 2005).   
Two additional factors that can impair cognition are directly within the control of 
the practitioners prescribing skill. Antipsychotic medication decreases the positive 
symptoms of schizophrenia by blocking the dopamine (D2) receptors.  But blocking too 
many receptors (greater than 80%) not only increases the risk of EPS, but also raises the 
risk of cognitive impairment (Sakurai et al., 2013).  The total percentage blocked was 
estimated by measuring plasma levels of the antipsychotic concentrations using a 
pharmokinetic model developed for the study.  Although this level of analysis is not 
common practice, the impact of antipsychotic medications in amounts high enough to 
cause these symptoms is important for practitioners to recognize.  Prescribing 
anticholinergic medications to the older patients to reduce the symptoms of EPS becomes 
the second factor that can damage cognition.  A study of 1,780 patients aged 70 years and 
older found using drugs with anticholinergic properties associated with low cognitive 
performance (Lechevallier-Michel, Molimard, Dartigues, Fabrigoule, & Fourrier-Reglat, 
2004).  Recognition and achieving the correct balance of receptor blocking would 
minimize the side effects while relieving symptoms.  Choosing the correct medication, 
dose, and monitoring for physical and cognitive changes is important for this older 
population.  
Physiologic changes as a product of aging place the elderly patients with 
schizophrenia at elevated risk for adverse drug reactions.  Two major organs of excretion, 
liver and kidney, deteriorate with aging.  This atrophy results in pharmacodynamic 
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changes that may alter the expected response of either organ to the effect of a medication 
(Hutchison & O’Brien, 2007).  This atrophy is further complicated when the patients’ 
renal and hepatic system is additionally challenged by disease that further confounds the 
process.  Uncontrolled diabetes and hypertension are known to damage the kidneys when 
symptoms management over time has been poor. This may lead to dialysis with severe 
drug and dietary restrictions.  As noted previously, hepatic function becomes impaired by 
the ravages of hepatitis and cirrhosis secondary to disease, alcohol or drug use, or poor 
lifestyle choices (Bowie, Serper, Riggio, & Harvey, 2005). 
Fluid balance and the ability of the aging body to absorb, process, and excrete 
successfully the antipsychotic medications both require close supervision. Diabetes, heart 
failure, or instances of dehydration can alter the excretion and concentration of 
medications by impacting blood levels of medications (Kaufman, 2011).  Liver 
impairment or disease may affect the efficiency of the metabolism of the drug (Sadock, 
Sadock, & Kaplan, 2011).  These examples may result in failure of the medications to 
manage psychotic symptoms as the quality of the organ function is impaired by the 
atrophy or disease.   
Polypharmacy 
In addition to the antipsychotic medications used to treat their mental illness, 
aging patients with schizophrenia are more likely to be prescribed statins, non-steroidal 
anti-inflammatories, insulin, antibiotics, diuretics, and modulators of kidney filtration and 
hypoglycemic agents.  Estimates indicate that 60% of drug reactions in older patients 
with schizophrenia are caused by the following medications:  glucocorticoids, 
hypoglycemics, nonsteriodal anti-inflammatories and antibiotics (Perry, 2011). As these 
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multiple medications are absorbed into the body, the neural pathway in which the 
medication activates becomes overloaded causing conflicting medication efficiency.  It is 
critical for practitioners to carefully assess the combined pharmacological profile of 
medical and psychiatric medications and their interactions within the aging body.  
Substance Abuse  
The comorbidities associated with schizophrenia in the elderly population may 
also be exacerbated by alcohol and/or drug use.  Binge drinking and non-medical use of 
prescription drugs rank high in the elderly population (Blazer & Wu, 2011). A decreased 
percentage of water in the aging body means less alcohol is necessary to cause 
intoxication (Flood & Buckwalter, 2009).  Alcohol and other drug use in the elderly may 
compound age-related declines in mental abilities.  Memory lapses, changes in sleep 
patterns, and sleep deprivation may be more common in those who use alcohol and other 
drugs.  Consequently, it is essential to identify substance abuse problems.  However, it is 
important to be aware that symptoms associated with substance abuse such as confusion, 
forgetfulness, poor diet, neglect of personal appearance, and hoarding may be 
misinterpreted as symptoms of schizophrenia (Flood & Buckwalter, 2009). 
Substance use may also result in falls or other accidents, especially in individuals 
with pre-existing impairment of vision, balance, or mobility.  Prolonged use of alcohol in 
particular can contribute to the development or exacerbation of conditions that alter the 
successful metabolism of medications (e.g. cirrhosis and chronic pancreatitis) or 
complicate the overall health of the aging patient in general (e.g. compromise immunity 
and hepatitis) (Hipwell, Singh, & Clark, 2000).  The use of alcohol in combination with 
antipsychotic medications alters the desired therapeutic effect of the antipsychotics 
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allowing break through psychosis to occur and an increased occurrence of side effects. 
Research examining the effect of alcohol on neuropsychological functioning noted a 
more severe decline in cognition (Mohamed, Bondi, Kasckow, Golshan, & Jeste, 2006).  
Additionally, a higher level of depression and non-compliance with prescribed 
medications were found in the substance abusing elderly population with schizophrenia 
(Margolese, Malchy, Negrete, Tempier, & Gill, 2004).   
The occurrence of medical comorbidities within the elderly population is an 
expected part of the aging process, but the degree of understanding that practitioners 
exercise in prescribing for these conditions can greatly alter the final desired outcome.  
The monitoring of MetS symptoms and cardiovascular disorders, the awareness of all 
medications within the aging body and of the potential for alcohol and substance abuse 
are important factors in caring for this population. Knowledge of the effects these issues 
have on older patients’ physical health will help provide the necessary identification to 
increase positive healthcare outcomes.   
Synergy Among Factors Influencing Medication Management 
 Maximizing all of the resources available to cope with health concerns in caring 
for the older population with schizophrenia may be the best approach for practitioners.  
Under-recognition and under-treatment of medical risk factors, the patients’ sedentary 
lifestyle or poor diet, and the contribution of adverse metabolic side effects from 
antipsychotic medications (weight gain, dyslipidemia, and hyperglycemia) can combine 
to undermine this population’s health outcomes.  By combining the behavioral, medical, 
and psychiatric interventions available, presenting issues can be treated more efficiently 
as a group rather than individually.  
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Additionally, a synergistic use of medications for treatment of the older 
population with schizophrenia would maximize the pharmacologic outcome with a 
minimum of complications from overloading the brain circuitry with polypharmacy.  For 
instance, use of one medication for psychosis as well as sleep or prescribing medication 
more energizing with less sedentary side effects for issues related to weight gain or 
ahedonia utilizes a synergistic approach. Management of schizophrenia for the older 
population requires a delicate balance of pharmacology skills and knowledge of the 
patient to achieve the optimum potential possible.   
Along with symptoms management of schizophrenia, there are many additional 
factors to be considered that may enhance the outcome of treatment.  Arranging more 
frequent monitoring and offering targeted symptom management and behavioral 
components of treatment influences outcomes. Blending medical and psychiatric visits 
for an all-inclusive picture of the older adult with schizophrenia for continuity of care 
would bring the most gain for the least output. For example, additional medication is 
indicated at times for depression, anxiety, mood stability, or co-occurring psychiatric 
condition. Practitioners must then choose the proper medication to provide symptom 
control without causing further complications.  Following up with the necessary 
monitoring of clinical indices for physical as well as mental areas of concern is indicated 
as part of the best practice care practitioners can provide. 
Addressing the necessary monitoring and points of concern that may alter the 
current path of treatment is part of synergistic assessment. This approach may draw from 
a variety of sources inside and outside practice to provide best care options for older 
patients with schizophrenia.  The focus is the patient as a whole.  Choosing what 
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components to initiate in addressing several issues at one time can maximize the limited 
resources in the ever-narrowing mental health arena.   
Project Focus 
This project involves a detailed analysis of the literature on medication 
management of older adults with schizophrenia in the community setting.  The objective 
of this project is to increase practitioners’ understanding of medication management by 
increasing the ability to provide comprehensive, quality-focused care for this special 
population. The literature is analyzed and ranked according to the strength and quality of 
the evidence by examining the relevant research in aggregate to determine the strength of 
the evidence, using the hierarchal method proposed by Melnyk and Fineout-Overholt 
(2005). The hierarchy contains seven levels with I being highest quality and VII lowest 
quality. The levels are based on the ability of the design to protect against threats to 
internal and external validity.  An evidence table will show the available literature 
analysis with the strongest data chosen as best practice recommendations.   
Evidence-based question. Creating evidence-based practice inquiry begins with a 
specific format.  This format, labeled PICOT (patient population, intervention of interest, 
comparison intervention or status and outcome, time), produces the best evidence and 
most relevant information (Melnyk & Fineout-Overholt, 2005).  The PICOT definitions 
are seen in Table 1.4. The EBP question is “In community dwelling older adult with 
schizophrenia, what is the best practice for antipsychotic medication management?”   
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Table 1.4 
PICOT Definitions 
Population Intervention Comparison Outcome Time 
Community 
dwelling older 
adults with 
schizophrenia 
Medication 
management for 
schizophrenia 
Changes in 
medication 
management 
because of drug 
actions and side 
effects, co-
morbidities, 
physiological 
changes due to 
disease and age 
Safe and 
effective 
medication 
management 
Current 
 
Summary 
 The expanding population of elderly individuals with complex health problems 
requires extensive comprehensive care.  Understanding the ever changing mental health 
system continues to provide challenges both providers and patients must navigate in order 
to be successful. The lack of clinical guidelines to manage older adults with 
schizophrenia will present unprecedented challenges for health care providers as this 
population grows. The aging bodies’ many ongoing changes, co-occurring medical and 
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psychiatric issues, multiple medications and providers, side effects, and the potential of 
substance abuse and non-compliance all cloud this navigation.  
 Selection of medications for the aging patient with schizophrenia requires careful 
analysis of factors including the patient’s age, the duration of time the patient was been 
treated with antipsychotic medication, and the individual patient’s health profile. 
Determination of appropriate antipsychotic medication presents the practitioner with 
myriad options.  Patient exposure to decades of antipsychotic medications with 
subsequent side effects warrants special practitioner attention.  However, use of 
medications within the older population, with aging body systems, requires extra scrutiny 
and vigilance to provide safe effective care.  
 Therefore, it is important for providers to be equipped with the knowledge to 
maximize patient outcomes.  Compiling, evaluating, and ranking the scattered literature 
relevant to the care of older adults with schizophrenia will provide clarity regarding the 
best clinical medication management.  In the following chapter, normal aging, 
schizophrenia, and medication issues will be examined by body systems to provide a 
context for the analysis of best-practice medication management for community dwelling 
older adults with schizophrenia. 
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Chapter 2  Physiological Analysis 
Patients who are 65 years and older with schizophrenia provide practitioners with 
multiple pharmacological challenges.  Although the speed at which aging occurs within 
the body is unique to each individual, aging ultimately results in a gradual slowing of the 
systems that govern the pharmacokinetic profile of medications.  Providers must consider 
these changes when prescribing medications for aging adults. Coupled with the 
complexity of antipsychotic medications, the task of prescribing for this population may 
seem daunting.  Pharmacological research focusing specifically on this population is 
historically limited because of the complicated health issues and polypharmacy 
presentations, as well as researchers’ ethical concerns over the manipulation of this more 
fragile group (Howard, 2010; Perry, 2011).  However, in preparation for the expansion of 
the geriatric population over the next quarter century, pharmacology research involving 
older adults is beginning to grow.  Geriatric psychopharmacologists suggest the 
relationship between the general medical and neurological conditions are closely 
associated with aging.  Careful focus on this connection may provide practitioners with 
improved options when choosing medications using this knowledge (Meyers & Jeste, 
2010).  In this chapter, the core points of antipsychotic medication management for older 
adults with schizophrenia are explored and common physiological issues important to 
safe and effective prescribing practice are identified.
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The three major focal points impacting medication efficacies for older patients with 
schizophrenia are physiological changes of normal aging (see Appendix A), 
physiological changes in schizophrenia (see Table 2.1), and effects of antipsychotic 
medications (see Table 2.2).  The effects of these three points on the person as a whole 
are discussed in the chapter’s narrative.  Table 2.3 presents a comparative examination of 
the interactions of normal aging, schizophrenia, and antipsychotic medications to explore 
the commonalities that complicate medication management in this population.  An 
understanding of these issues will provide a basis for an exploration of the literature to 
determine best practice to improve medication success and positively impact the quality 
of care provided to this population. 
Physiological Changes of Normal Aging by Body System 
Pathophysiology researchers have found alterations in body function associated 
with aging (see Appendix A). Certain physiological changes of aging specifically 
influence the pharmacological treatment of older patients with schizophrenia.  
An understanding of changes within the aging adult’s body is essential when considering 
medical interventions for older patients with schizophrenia. First, aging leads to a gradual 
diminished functional capacity of the organ systems.  Cardiovascular, central nervous 
system, and respiratory changes have the largest effect with reduction of blood flow, lack 
of oxygen, and diminished stimulation to target organs.  The net effect is reduced size, 
decreased function, altered absorption, and regeneration issues leading to loss of efficient 
cellular function of the organs.  
 The reduced cellular functions within the organs predispose the older patient to 
reduced capacity or failure of the systems.  These changes can result in myocardial 
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infarctions (MI’s), coronary artery disease (CAD), hyperglycemia, and a higher potential 
for fractures and falls.  The bases of the lungs are less ventilated resulting in an 
ineffective redistribution of blood to compensate.  This results in falling oxygen levels 
that become worse when the older adult is lying down, causing a risk for respiratory 
failure.  Surgery, bed rest, pulmonary edema, trauma, burns, or environmental events 
exacerbate this hypoxic condition (McDaniel, 1992). 
The altered physiology within the cellular functioning also impacts the 
pharmokinetic values in the elderly.  The distribution of medication is altered by the 
change in the proportion of water and body fat present.  Hydrophilic drugs may have a 
smaller volume of distribution and concentrations could be higher than normal.  
Lipophilic drugs could have an increased volume of distribution with a potentially 
prolonged half-life (Shi & Klotz, 2011).  Decreased serum albumin concentrations could 
increase unbound plasma concentrations of highly protein-bound medications.   
Decreased hepatic and renal function could also slow the clearance of metabolites and 
drugs from the liver and kidneys to increase the drugs’ half-life (Cusack, 2004).   
The addition of disease pathology overloads the system.  Similarly, lifestyle 
choices affect the baseline wellbeing of the individual.  Polypharmacy issues may 
complicate or overwhelm the entire system as medical and psychiatric medications are 
prescribed.  All of these factors would have a compounding negative effect on the overall 
body of the aging patient.  Alterations in physiological functioning associated with 
schizophrenia have the potential to exacerbate changes individuals are already 
experiencing as an expected result of the aging process. The physiological changes of 
schizophrenia by body system are examined next.  
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Table 2.1 
Physiological Changes in Schizophrenia by Body System 
Cardiovascular 
• Increased risk of cardiovascular comorbidity, coronary artery disease, hypertension, 
and altered lipid levels (Saha et al., 2007) 
• Decreased estrogen levels associated with increased blood pressure and decreased 
nitric oxide, increasing the risk of CV disorders and myocardial infarctions 
(Hennekens et al., 2005) 
• Peripheral endothelial tissue dysfunction increases morbidity (Israel et al., 2011) 
Hematologic 
• Increased presence of hyperlipidemia, hyperprolactinemia, and hyperglycemia 
(Halbreich, Kinon, Gilmore, & Kahn, 2003) 
• Impaired peripheral glucose metabolism with elevated glucose levels and 
hemoglobin A1C (Steiner et al., 2012) 
Respiratory 
• Increased risk of chronic obstructive pulmonary disease (COPD), deteriorating lung 
capacity, and respiratory problems (Leucht, Burkard, Henderson, Maj, & Sartorius, 
2007) 
• Small increase in lung cancer risk (Barak, Achiron, Mandel, Mirecki, &Aizenberg, 
2005) 
Gastrointestinal 
• Increase in BMI and central adiposity (Steiner et al., 2012) 
• Small decrease in risk for colorectal cancer (Barak et al., 2005) 
Urinary 
• Neurogenic bladder associated with Neuroleptic Malignant Syndrome (NMS) 
(Caroff, Campbell, & Sullivan, 2007) 
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Endocrine 
• Increased risk of hypothyroidism (Carney, Jones, & Woolson, 2006) 
• Increased risk of diabetes mellitus 
• Increased occurrence of insulin resistance (Steiner et al., 2012) 
Neurological 
• Impaired cerebral glucose metabolism, especially the frontal lobe (Ward, Friedman, 
& Schulz, 1996) 
• Right lateral fusiform gyrus dysfunction causing impairment of facial recognition 
and processing, contribute to social dysfunction (Quintana, Wong, Ortiz-Portillo, 
Marder, & Mazziotta, 2003)  
• Oligodendrocyte and myelin dysfunction associated with changes in synaptic 
function and formation lead to progressive, mild cognitive impairment (Takahashi, 
Sakurai, Davis, & Buxbaum, 2010) 
• Decreased muscarinic and nicotinic receptors in caudate-putamen, hippocampus, and 
selected regions of prefrontal cortex impair regulation of cognitive neurotransmitters 
(Eyler, Kemp, Mirzakhanian, & Jeste, 2009) 
• Loss of GABAenergic neurons and inhibitory interneurons is associated with 
hippocampus hyperactivity, ventral hippocampus regulates dopamine neurons 
responsivity (Grace, 2012) 
• Decreased 5-HT2A receptors, increased striatal D2 receptors with increased 
dopamine content or metabolism (Wong & Tol, 2003) 
• Selective neuronal degeneration within the norepinephrine reward neural system 
contributing to ahedonia (Karim et al., 2005) 
• Loss of brain volume from reduced density of the axons, dendrites, and synapses 
mediating brain's associative functions (Ward et al., 1996) 
• Lateral and third ventricular enlargement and reduction in cortical volume (grey 
matter) by up to 25% (Pantelis et al., 2005)  
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• Grey Matter Volume (GMV) in superior temporal gyrus (STG) associated with 
positive symptom severity, white matter impairment increases negative symptoms, 
GMV reduced in temporal and mediofrontal cortex involved in positive symptoms 
• Increased density of interstitial white matter neurons correlates to grey matter 
interneuron deficit in the cortex (Rusch et al., 2007) 
• Reduced symmetry in temporal, frontal, and occipital lobes 
•Decreased amygdala, hippocampus, temporal and parahippicampal gyrus sizes cause 
disturbance in limbic system and glutamate transmissions causing difficulty filtering 
out incoming data, brain responds by releasing dopamine (Baiano et al., 2007) 
• 30-45% thalamus volume reduction and sub nuclei neuronal loss (Ettinger et al., 
2001) 
• Dysfunction of anterior cingulate basal ganglia thalamocortical circuit (positive 
psychotic symptoms) and dorsolateral prefrontal circuit (negative symptoms) 
•N-acetyl asparatate were lower in hippocampus and frontal lobes impairing neural 
metabolism (Wong & Tol, 2003) 
• Abnormal EEG with increased sensitivity to activation procedures, increased theta 
and delta activity, decreased alpha activity, causing epileptiform activity, and more 
left-side abnormalities (Nuechterlein & Dawson, 2002) 
• Eye movement dysfunction with inability to follow moving target accurately, 
disinhibition of saccadic eye movements (Alain, Hargrave, & Woods, 1998) 
• Dysdiadochokinesia, astereognosis, primitive reflexes, and diminished dexterity 
(Irani et al., 2011) 
Immune 
• Decreased T-cell interleukin (IL)-2 production, reduced number and responsiveness 
of peripheral lymphocytes, abnormal cellular, humeral reactivity to neurons, and 
presence of brain-directed (antibrain) antibodies 
• Increased concentration of IL-1, IL-6, TGF-β, state markers and IL-12, IFN-λ, TNF-
α, and sIL-2R are trait markers of the disease 
• Elevated C-reactive protein, oxidative stress markers (Steiner et al., 2012)  
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• Increased apoptosis may account for tumor resistance with tumor suppression 
indicating a decreased incidence of cancer (Barak et al., 2005) 
• Hyperprolactinemia alters the modulation of mononuclear cells of immune-cell 
function (Halbreich et al., 2003)  
• Reduced length of telomeres causing cellular degeneration and premature cell death 
(Jeste et al., 2011) 
Musculoskeletal 
• Increased prolactin levels causing hypogonadism increasing risk of osteoporosis 
(Halbreich et al., 2003) 
• Abnormal performance on cerebellar-dependent tasks with decreased complexity of 
postural sway; abnormal changes in association with removal of visual input causing a 
disturbance of gait (Kent et al., 2012) 
• Decreased risk of rheumatoid arthritis (Leucht et al., 2007) 
Reproductive:  Female 
• Small increased breast cancer risk at younger age, and higher risk for post-
menopausal women (Barak et al., 2005) 
• Increased prolactin levels cause decrease in estrogen levels with potential decreased 
libido or anorgasmia (Halbreich et al., 2003) 
Reproductive:  Male 
• Increased prolactin levels cause decreased estrogen levels and libido, ED, delayed 
orgasm, anorgasmia, retrograde or painful orgasms (Halbreich et al., 2003)  
• Small to medium decrease in prostate cancer (Barak et al., 2005) 
Sensory:  Vision & Olfactory 
• Elevated blink rate (hyperdopaninergic) (Ross et al., 1999) 
• Abnormalities in olfactory receptor neurons with decreased ability to detect and 
identify odors (Turetsky et al., 2003) 
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Skin & Hair 
• Small to medium decrease of malignant melanoma (Barak et al., 2005)  
 
Physiological Changes in Schizophrenia by Body System 
 Studies have shown schizophrenia to be a life-altering disease.  Compared to the 
general population, individuals with schizophrenia experienced accelerated physical 
aging with increased and premature medical comorbidities and mortality (Jeste et al., 
2011).  Researchers have identified several common physiological changes inherent in 
patients with schizophrenia.  In younger patients with schizophrenia, a high proportion of 
deaths are caused by suicide and accidents. Yet a substantial remaining proportion of 
mortalities is due to physical illness (Brown, 1997).  These illnesses may be influenced 
by physiological changes associated with schizophrenia (see Table 2.1).    
The main changes that occur within the body systems with the presence of 
schizophrenia begin in the brain.  Many of these changes bring about the positive and 
negative symptoms of schizophrenia by affecting dopamine levels within the cortex.  
Other changes affect the transmission of the neurochemicals within the brain, causing 
alterations in cognition, the capacity to feel pleasure, and the ability to identify people, 
objects, and events.  Throughout the cardiovascular system there are increased risks of 
heart disease, hypertension, and dyslipidemia with premature cellular death and lessened 
immune responses to protect the vascular system from damage.  Hyperglycemia and 
insulin resistance occur at a higher level in this population, which leads to a higher 
percentage of diabetics.   
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 The etiology of the physiological changes associated with schizophrenia is 
unclear. Questions remain regarding whether individuals with schizophrenia develop 
health issues contributing to reduced life expectancy and comorbid health issues, or 
whether there are associated factors.  These would include unhealthy lifestyle choices, 
antipsychotic medications, or disease-inherent derangements predisposing them to these 
problems.  With the knowledge of aging and the effects of schizophrenia on the body 
systems of the older individuals, an understanding emerges that provides insight for 
practitioners to guide practice decisions.  Table 2.2 examines medication commonly 
prescribed for the treatment of schizophrenia and the many ways the presence of this 
medication alters the functioning of body systems.  This additional layer will complement 
the total knowledge compiled and provide a basis for targeted analysis of problem areas 
important for best practice care.   
Effects of Antipsychotic Medications  
 In considering the prescribing practices for older patients with schizophrenia, it is 
important to be aware of medication side effects, actions, and class warnings. The 
information given by the FDA helps providers monitor potential side effects, offer 
cautions for harmful drug/drug interactions, and guides precautionary details necessary 
for safe prescribing practice.  This section provides a table illustrating these factors and a 
narrative overview of the most important findings.  The two classes of antipsychotic 
medications are examined through the effects, both positive and negative, on each body 
system.  Special warnings governing the prescribing practices for specific drugs are noted 
within the table. 
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The FDA’s Warnings 
The Food and Drug Act of 1906 prompted the formation of the Food and Drug 
Administration (FDA), the governing public health and consumer protection agency in 
the USA.  Under the approval and sanctions of this office, prescribers operate and utilize 
FDA guidelines for safe use of medication.  Drugs are subjected to rigorous testing with 
proof of safety carefully examined.   
The FDA issues warnings or alerts on the package inserts (PI) that accompany all 
drugs to market and guide labeling and Physician Desk Reference (PDR) listings. The 
strongest warning is the boxed warning (also called a bolded or black box warning).  This 
indicates that the drug carries a significant risk of serious or even life-threatening adverse 
effects. Warning and precautions do not meet the definition of serious adverse reaction, 
but are clinically significant events that may: (a) lead to potentially serious outcomes 
unless dosage or regimen is adjusted, (b) require monitoring to prevent or manage the 
potential of an adverse reaction, and (c) affect patient compliance when compliance has 
potentially serious consequences (“Guidance for industry,” 2011). When the warning 
extends to all the drugs in one class of medications, it is called a class warning. Class 
warnings are typically issued when an across-the-board side effect is noted.   
In 2003, the FDA issued a black box warning on all antipsychotic medications 
written for the elderly with dementia because of sudden cardiac death risk (Leon et al., 
2010). Initially, the concern was an increase in cerebral vascular accidents including 
strokes. The warning was amended to include increased risk of mortality related to 
sudden cardiac death (Jouk et al., 2006).  Further study revealed a risk of death in drug-
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treated patients between 1.6 and 1.7 times the risk of death in placebo-treated patients 
(Strompf, 2012). Questions arise as to the best practice for treatment of the elderly patient 
with schizophrenia who additionally suffer from dementia, as both disorders must be 
addressed to provide quality care (Harris, Heaton, Schalz, Bailey, & Patterson, 1997).   
 Warnings regarding medications are areas continually revised and updated by the 
FDA.  The FDA sponsors contact sites via the web, consumer phone reporting, and 
professional med watch e-lists to keep prescribers up to date on recalls, shortages, and 
amendments to the PI (“MedWatch,” 2013).  Safe medication prescription depends on 
knowing the latest information and applying this information to the care of individual 
patients.   
It is also critical for prescribers to understand the effects of antipsychotic 
medications on the body.  The actions and side effects (see Table 2.2) from the first 
generation antipsychotic, dopamine 2-receptor antagonist (D2RA) class, to the newer 
generation of neuroleptic medications, serotonin dopamine antagonist (SDA) class, are 
different in many ways with a few similarities.  The degree the patient experiences these 
side effects is also patient specific, but the trend tends to follow the side effect potential 
in Table 2.2. 
With the discovery of the first antipsychotic medication in the mid-twentieth 
century, the potential for enhancing the lives for patients with schizophrenia opened up to 
new possibilities.  However, over time, adverse response to these new medications 
became apparent.  
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Table 2.2 
Effects of Antipsychotic Medications by Body System 
Cardiovascular 
D2 receptor antagonist (D2RA) 
Site/action specific Interactions Adverse reactions 
• Alpha-1 receptor 
antagonist 
• Decreased blood pressure, 
orthostatic hypotension 
• Increased risk of 
events in elderly 
dementia patients 
(Stahl, 2008) 
• Class warning (all) 
• Fainting, falls 
• Class warning (all) • Elevated prolactin 
level (Miller, 2004) 
• Cigarettes and alcohol 
consumption may also 
impact outcome 
• Low estrogen, higher blood 
pressure, and decreased nitric 
oxide increase chance of 
myocardial infarction 
• Lower potency DRAs 
more cardio toxic than high 
potency drugs 
• Caution with other drugs 
that may increase QT 
interval to compound the 
event (Thorazine, Haldol, 
Mellaril drug specific) 
• Arrhythmias, postural 
hypotension, cardiac arrest 
• Torsades de Pointes (TdP) 
(with IV use and or higher 
doses) 
• Thorazine specific: T-wave 
blunting, depression of the ST 
segment 
  
• Disrupted enzyme 
contractility in cardiac 
cell, decreased cardiac 
contractility, increased 
circulating 
catecholamines,  
prolonged arterial and 
ventricular conduction 
refractory periods 
(Stahl, 2008)  
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Serotonin-dopamine antagonist (SDA) 
Side effects Interactions Adverse reactions 
• Weight gain, glucose 
dysregulation, and lipid 
abnormalities  
• Class warning (all) • Increased cardiovascular 
events 
• Alpha-1 receptor 
antagonist  
• Class warning (all) • Fainting, falls 
• Increased risk of 
events in elderly 
patients with dementia 
(Strompf, 2012) 
• Class warning (all) • Death 
• Increased visceral 
obesity (Steiner et al., 
2012) 
• Increased pro-
inflammatory cytokines 
and elevated C-reactive 
protein (CRP) levels 
• Increased complications 
• Clozapine specific:  
Increased risk of 
myocarditis, pericardial 
effusion, congestive 
heart failure, and 
cardiomyopathy, 
(Strompf, 2012) 
• 25% tachycardia noted • Associated with higher risk 
during first month of treatment 
• Clozaril, Invega, 
Saphris, Fanapt, 
Geodon, Seroquel, 
Saphris specific: 
Prolonged QT interval  
• Caution with other drugs 
that may increase QT 
interval to compound the 
event 
• Arrhythmias, cardiac arrest  
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• Risperidone, Invega, 
Latuda, Seroquel 
specific: Elevated 
prolactin (Strompf, 
2012) 
• Cigarettes and alcohol 
consumption may also 
impact outcome 
 • Increased risk of 
cardiovascular disorders 
Hematologic 
D2 receptor antagonist (D2RA) 
Site/action specific Interactions Adverse reactions 
• Agranulocytosis, 
thrombocytopenia or 
nonthrombocytopenic 
purpura, hemolytic 
anemia, pancytopenia 
can occur (rarely) 
• Leukopenia, 
neutropenia, and 
agranulocytopenia 
(Strompf, 2012) 
 
• Class warning (all) • Mortality rate is 30% 
Serotonin-dopamine antagonist (SDA) 
Site/action specific Interactions Adverse reactions 
• Leukopenia, 
neutropenia,and 
agranulocytopenia  
• Class warning (all) • Compromised immune system 
• Elevated fasting 
triglycerides, insulin 
resistance  
• Class warning - Initial 
symptoms of metabolic 
syndrome 
• Increased appetite and weight 
gain (variable by drug) 
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• Clozaril specific: 
Significant risk of 
potentially life-
threatening 
agranulocytosis  
• Drop in white blood cells 
(WBC) and absolute 
neutrophil count (ANA) 
• Compromised immune system 
and possible death 
• Seroquel, Zyprexa 
specific:  
Hyperlipidemia 
(Strompf, 2012) 
  • Increased risk of 
cardiovascular events 
Respiratory 
D2 receptor antagonist (D2RA) 
Site/action specific Interactions Adverse reactions 
• Blockage of 
muscarinic cholinergic 
receptors (Stahl, 2008) 
• Decreased bronchial 
secretions 
• Mucous occluding small 
airways in patients with asthma 
or bronchitis 
• Increased risk of 
bronchial pneumonia 
(Strompf, 2012) 
• Sedation, decreased 
secretions, hypoventilation, 
dehydration, and 
hemoconcentration 
contribute 
• Compromised respiratory 
system 
• Mellaril specific:  
Central nervous system 
depression (Strompf, 
2012) 
• Enhanced by use with 
sedative/hypnotic 
• Respiratory depression with 
distress potential 
Serotonin-dopamine antagonist (SDA) 
Site/action specific Interactions Adverse reactions 
• Blockage of 
muscarinic cholinergic 
receptors (Stahl, 2008) 
 
• Decreased bronchial 
secretions 
• Mucous occluding small 
airways in patients with asthma 
or bronchitis  
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Gastrointestinal 
D2 receptor antagonist (D2RA) 
Site/action specific Interactions Adverse reactions 
• Muscarinic 
cholinergic receptor 
blockade (less with 
Haldol) (Stahl, 2008) 
 
• Decreased salivation • Dry mouth, constipation, 
dental caries, ulceration of 
gums, and buccal mucosa 
Serotonin-dopamine antagonist (SDA) 
Site/action specific Interactions Adverse reactions 
• Drug specific bias 
(espy. Clozapine, 
Zyprexa, Saphris, 
Latuda, Seroquel):  
Weight gain (Strompf, 
2012) 
 
• May be compounded by 
other weight-causing drugs 
• Weight gain - Frequently a 
cause of discontinuation 
• Muscarinic 
cholinergic receptor 
blockade (Stahl, 2008) 
 
• May be compounded by 
other drying medications 
• Decreased salivation 
• Esophageal 
dysmotility 
• Drug specific: Seroquel • Blockage, N/V 
• Invega specific:  
gastric narrowing 
  • Blockage and stricture 
potential when GI disease 
present 
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• Risperidone specific:  
Dysphagia  (Strompf, 
2012) 
 
 
  • Difficulty swallowing 
Urinary 
D2 receptor antagonist (D2RA) 
Site/action specific Interactions Adverse reactions 
• Muscarinic 
cholinergic receptors 
blockage 
• Difficulty urinating • Bladder distention, urinary 
retention 
Serotonin-dopamine antagonist (SDA) 
Site/action specific Interactions Adverse reactions 
• Muscarinic 
cholinergic receptors 
block. (Stahl, 2008) 
 
  • Bladder distention, urinary 
retention 
Endocrine 
Serotonin-dopamine antagonist (SDA) 
Site/action specific Interactions Adverse reactions 
• Endocrine bioactivity 
from excess visceral 
adipose tissue 
increasing systemic 
inflammation (Buckley, 
Miller, Singer, Arena, 
& Stirewalt, 2005)  
• Synthesize and release 
bioactive molecules: 
Interleukin  (IL)-1, Il-6, 
Tumor Necrosis Factor 
(TNF), increased 
monocytes and CRP  
• Reduced insulin resistance, 
induce insulin resistance of the 
insulin-sensitive glucose 
transporter in the peripheral 
tissue 
                                                      
• Elevated triglycerides (with or 
without weight gain) 
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• Postsynaptic M3 
muscarinic cholinergic 
receptor blockage (high 
probability with 
Olanzapine, Clozapine) 
(Lipscombe et al., 
2011).  
 
• Reduces insulin release- 
Beta cell failure 
• Hyperglycemia, diabetic 
ketoacidosis (DKA) and 
hyperosmolar syndrome (HHS) 
• Hyperglycemia, 
diabetes mellitus risk 
increased (Okumura et 
al., 2010)  
 
• Class warning (all) • Metabolic syndrome 
Neurological 
D2 receptor antagonist (D2RA) 
Site/action specific Interactions Adverse reactions 
• Blockade of the D2 
receptors in the 
mesolimbic dopamine 
pathway, reducing the 
hyperactivity of the 
pathway 
• Reduction of the positive 
symptoms of schizophrenia 
  
• Blockage of the D2 
receptors in the 
nigrostriatal DA 
pathway 
• Blockage by dopamine 
may allow acetylcholine 
levels to become 
overactive. Class warning. 
Receptors become sensitive 
over time and upregulate 
• Increased risk of EPS and TD 
High discontinuing rate due to 
unacceptable side effects 
• D2 antagonist reduced 
in the tuberinfundibular 
pathway 
• Prevents dopamine from 
binding to D2 receptors 
• Elevated prolactin levels  
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• D2 receptor 
antagonist in the 
mesocortical pathway 
to the dorsolateral 
prefrontal cortex  
• Reduced dopamine • Cognitive and negative 
symptoms 
• D2 receptors blocked 
in mesocortical DA 
pathway to 
ventromedial prefrontal 
cortex (Stahl, 2008) 
• Reduced dopamine • Affective and negative 
symptoms 
• Neuronal brain 
changes (Dean, 2006) 
• Neurotoxicity, apoptosis, 
DNA fragmentation, 
deficits in DNA repair, 
deficits in function of the 
mitochondrial respiratory 
chain, and changes in 
levels of Neurotrophic 
factors (NTF)  (observed in 
rodents) 
 
• Unknown  
• Histamine 1 receptor 
antagonist. 
  • Drowsiness, increased 
appetite, with high 
discontinuing rate as a result 
• Alpha 1 inserted   • Dizziness, drowsiness 
• Block D2 receptors in 
the mesocortical and 
mesolimbic DA 
pathway (Stahl, 2008) 
  • Causes or exacerbates 
negative or cognitive symptoms 
• Blockage of 
muscarinic cholinergic 
receptors (Strompf, 
2012) 
 
• Class warning (all) • Cognitive blunting, 
drowsiness, memory 
impairment, and confusion 
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• Lower seizure 
threshold  
• Class warning (all)                                
• Lower potency drugs are 
higher epileptogenic 
• Higher incidence of seizures if 
pre-existing seizure disorder 
present 
 
• Neuroleptic 
Malignant Syndrome 
potential (Strompf, 
2012) 
 
• Class warning (all) • Death possible without 
treatment and rapid recognition 
of symptoms 
Serotonin-dopamine antagonist (SDA) 
Site/action specific Interactions Adverse reactions 
• 5HT2A antagonist 
occupies 5HT2A 
receptors on 
mesolimbic dopamine 
neuron causing 
dopamine release. 
• Cognitive, affective, and 
negative symptoms are 
reduced  
  
• 5HT1A (inhibitory) 
and 5HT2A 
(excitatory) regulate the 
dopamine release. 
5HT2A antagonist 
blocks serotonin 
excitation of the 
cortical pyramidal cells 
decreasing   glutamate 
release, reducing the 
hyperactive drive on 
the mesolimbic 
dopamine pathway 
downstream  
• Reduced hallucinations 
and positive symptoms                                                 
• Reduced binding 
(disinhibition) at D2 
receptor also decreased 
EPS 
  
• Dopamine regulation 
in the mesocortical 
• Mediate affective, 
cognitive, and negative 
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pathway symptoms 
• D2 receptors blocked 
in the nigrostriatal DA 
pathway (Stahl, 2008). 
• Class warning/Drug 
specific: All in class except 
Clozaril                                          
• Receptors become 
hypersensitive or 
upregulate  
• Initially hyperkinetic 
movements, over time 
developing into TD  
• Increase in seizure 
activity (Clozaril 
highest). 
• Class warning: Incidence 
occurs with higher doses 
• Higher incidence of seizures if 
pre-existing seizure disorder  
• Potential for cognitive 
and motor impairment 
• Class warning (all)  • Impaired use of motor 
equipment 
Immune 
D2 receptor antagonist (D2RA) 
Site/action specific Interactions Adverse reactions 
• Elevated prolactin 
level 
• Class warning  • Decreased immune response 
• Leukopenia, 
neutropenia, and 
agranulocytosis 
 
• Class warning (all) • Immunocompromised 
Serotonin-dopamine antagonist (SDA) 
Site/action specific Interactions Adverse reactions 
• Bioactive activity 
from visceral adiposity 
(Steiner et al., 2012) 
• Synthesize and release 
bioactive molecules: 
Interleukin (IL)-1, Il-6, 
Tumor Necrosis Factor 
(TNF), increased 
monocytes and CRP 
• Pro-inflammatory response 
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• Leukopenia, 
Neutropenia, and 
Agranulocytosis 
(Strompf, 2012 
) 
• Class warning (all) • Immunocompromised 
• Elevated prolactin 
level (Halbreich et al., 
2003) 
• Class Warning/Drug 
specific: Invega, Risperdal, 
Seroquel, and Latuda 
 
• Decreased immune response 
Musculoskeletal 
D2 receptor antagonist (D2RA) 
Site/action specific Interactions Adverse reactions 
• Elevated prolactin 
level (Meaney, 2004) 
• Class warning (all): 
hypogonadism 
• Increased risk of osteoporosis 
• Blockade of the 
dopamine receptors in 
the basal ganglia 
(Strompf, 2012) 
• Class warning/Drug 
specific: All in class except 
Clozaril 
• Movement disorders:  
Akathisia, TD, EPS, and 
hyperkinesis 
Serotonin-dopamine antagonist (SDA) 
Site/action specific Interactions Adverse reactions 
• Blockade of the 
dopamine receptors in 
the basal ganglia 
(Strompf, 2012) 
• Class warning/ Drug 
specific- All in class but 
Clozaril Incidence less than 
D2RA 
• Movement disorders:  TD 
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• Potential for akathisia • Drug specific: Abilify,  
Risperdal 
• Restless legs with "inner 
restlessness" causing inability 
to sit 
• Elevated prolactin 
level (Strompf, 2012) 
• Class warning/Drug 
specific (Risperdal, Invega, 
Seroquel, Latuda): 
hypogonadism 
• Increased risk of osteoporosis 
Reproductive (Male) 
D2 receptor antagonist (D2RA) 
Site/action specific Interactions Adverse reactions 
• Elevated prolactin 
level  
• Class warning: Disruption 
of the hypothalmis-
pituitary-gonadal system 
 
• Decreased libido and arousal, 
un- or hypo-orgasmia, 
galactorrhea 
• α-1 adrenergic 
antagonist activity 
(Strompf, 2012) 
 
  • Priapism, painful orgasm 
Serotonin-dopamine antagonist (SDA) 
Site/action specific Interactions Adverse reactions 
• Elevated prolactin 
level (Invega, 
Risperdal, Seroquel, 
and Latuda specific) 
 
• Class warning: Disruption 
of the hypothalmis-
pituitary-gonadal system 
• Decreased libido and arousal, 
un- or hypo-orgasmia, and 
galactorrhea  
• Increased risk of 
priapism 
• Drug specific: Fanapt, 
Seroquel, Risperdal, and 
Invega 
• Requiring medical attention 
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• Blockage of 
muscarinic cholinergic 
receptors (Strompf, 
2012) 
 
  • Sexual side effects 
Reproductive (Female) 
D2 receptor antagonist (D2RA) 
Site/action specific Interactions Adverse reactions 
• Elevated prolactin 
level 
• Class warning: Disruption 
of the hypothalmis-
pituitary-gonadal system 
• Disruption of the menstrual 
cycle, anovulation, 
galactorrhea, low estrogen 
level, increased risk of breast 
cancer (post-menopausal, pre-
menopausal), and decreased 
libido 
 
Serotonin-dopamine antagonist (SDA) 
Site/action specific Interactions Adverse reactions 
• Elevated prolactin 
level (Invega, 
Risperdal, Zyprexa, and 
Latuda specific) 
• Class warning:  
Disruption of the 
hypothalmis-pituitary-
gonadal system 
• Decreased libido and arousal, 
un- or hypo-orgasmia, 
galactorrhea, low estrogen 
levels, increased risk of breast 
cancer (post-menopausal, pre-
menopausal), and decreased 
libido 
• Increased risk of 
priapism 
• Drug specific: Fanapt, 
Seroquel, Risperdal, and 
Invega 
 
• Requiring medical attention 
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• Elevated prolactin 
level (Invega, 
Risperdal, Zyprexa, and 
Latuda specific) 
(Strompf, 2012) 
• Disruption of the 
hypothalmis-pituitary-
gonadal system 
• Decreased libido and arousal, 
un- or hypo-orgasmia, 
galactorrhea, low estrogen 
levels, increased risk of breast 
cancer (post-menopausal, pre-
menopausal), and decreased 
libido 
 
Sensory 
D2 receptor antagonist (D2RA) 
Site/action specific Interactions Adverse reactions 
• Blocked muscarinic 
cholinergic receptors 
  • Blurred vision 
• Retinal pigmentation • Drug specific:  Most 
associated with Mellaril 
• Early symptoms are nocturnal 
confusion related to night 
vision, may progress to 
blindness 
• Closed angle 
glaucoma, ocular 
dystonia, and cataracts 
(Strompf, 2012) 
• Usually associated with 
high dose and prolonged 
use especially Thorazine 
and Mellaril 
• Blurred vision, loss of vision, 
and blindness if untreated 
• Dysregulation of the 
bodies’ core 
temperature. (Strompf, 
2012) 
• Class warning • Caution in conditions that may 
elevate core temperature (e.g., 
exercising strenuously, 
exposure to extreme heat, 
dehydration) 
Serotonin-dopamine antagonist (SDA) 
Site/action specific Interactions Adverse reactions 
• Closed angle 
glaucoma, ocular 
dystonia 
  • Blurred vision, loss of vision, 
and blindness if untreated 
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• Dysregulation of the 
bodies’ core 
temperature. (Strompf, 
2012) 
• Class warning • Caution in conditions that may 
elevate core temperature (e.g., 
exercising strenuously, 
exposure to extreme heat, 
dehydration) 
• Increased chance of 
cataracts (Strompf, 
2012) 
• Drug specific (Geodon, 
Seroquel) with long time 
treatment 
  
 Skin  
D2 receptor antagonist (D2RA) 
Site/action specific Interactions Adverse reactions 
• Photosensitivity, 
allergic dermatitis 
• Drug specific: Thorazine 
has high correlation to skin 
changes 
• Severe sunburn appearance or 
long-term blue-grey 
discoloration of skin resolves 
when medication discontinued  
• Macularpapular, 
urticarial, petechial, 
and edematous 
eruptions (Strompf, 
2012) 
• May resolve 
spontaneously 
  
Mood and Behavior 
D2 receptor antagonist (D2RA) 
Side Effects Interactions Adverse Reactions 
• Increased risk of 
suicide 
• Class warning (all) 
  
• Elevated prolactin 
level 
• Class warning causing 
decreased estrogen 
• Hostility, anxiety, and 
depression 
Serotonin-dopamine antagonist (SDA) 
Site/action specific Interactions Adverse reactions 
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• Increased risk of 
suicide 
• Class warning (all). 
Special caution with 
antidepressant use   
• Drug specific: Invega, 
Risperdal, Seroquel, 
Latuda elevated 
prolactin level 
(Strompf, 2012) 
• Class warning causing 
decreased estrogen 
• Hostility, anxiety, and 
depression 
 
 Both classes of antipsychotic medications, D2RA and SDA, have a major impact 
on the overall health of the patient with schizophrenia.  As a class in general, the D2RA 
historically had more issues with movement disorders, prolactin elevations, and cardiac 
arrhythmias.  The SDA have been associated with more metabolic issues including 
weight gain, dyslipidemia, and insulin resistance. Over time, the SDA have had added 
prolactin issues and movement disorders associated with use.  It is paramount to see 
knowledge of antipsychotic medications as an evolving process. 
 The FDA web site offers updates to each drug with letters and addenda listed with 
changes to the PI by date.  Frequent updates of prescriber knowledge are necessary to 
keep up to date with the newest findings of the FDA.  Seminars and web-casts are offered 
to providers and most states require continuing hours of education for license renewal in 
medication updates.  Drug representatives of specific antipsychotic medication are 
usually a good source of new information on their products as well.  Changes occur on a 
continuous basis and safe prescribing practice requires practitioner attention.    
 In reviewing the depth to which these medications affect the body systems, the 
age-related changes in peripheral and central pharmacokinetics contribute to the variable 
degree of drug sensitivity in older age patients.  Age-related changes contribute to 
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increased sensitivity to side effects along the treatment pathway.  However, absorption 
factors and plasma concentration of antipsychotic medication are subject to the 
influencing factors of smoking and renal dysfunction as causative factors of altered 
clearance levels of medication.  Pharmacodynamic changes within the dopaminergic 
system interfere with antipsychotic sensitivity, and dosing for this population may need 
adjustments to compensate.   
 Knowledge of the data in this medication table and performing careful 
assessments of the older patient with schizophrenia allows a safety net to develop.  Once 
in place, guidelines can be set and patients can be monitored for individualized changes.  
With the use of medication, the patient has the chance of functioning free of the positive 
symptoms of the disease.  Awareness of negative symptoms and system involvement is 
the cornerstone of best practice care.  
 Cross Correlation of Aging, Schizophrenia, and Antipsychotic Medications 
 Elderly patients with schizophrenia are susceptible to the compounding factors of 
age, disease state, and the onboard effect of prescribed medications.  Research examined 
many of these factors, but stopped short, in many cases, of closely inspecting how these 
factors may interact to create treatment challenges. Table 2.3 illustrates correlations 
across the previous tables to identify key focal points for practitioners. Included in the 
table are items that appear in two or more tables across one body system, indicating areas 
that require particular attention or monitoring by providers because of their potential to 
interact in ways that complicate patient treatment.  Table 2.3 supports this paper’s 
premise that the best practice focus is on medication management considering drug 
actions, side effects, and comorbidities along with physiological changes associated with 
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both aging and schizophrenia. Geriatric psychopharmacologists must explore all aspects 
of the older patient with schizophrenia — physical, medical and psychiatric— to 
determine best practices for medication management.  
 Five main areas of concern for practitioners treating this population require 
greater attention:  metabolic syndrome, immune system depression, increased risk of 
respiratory disease, cognitive impairment, and cardiovascular disease. 
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Table 2.3 
Correlations Identified by Body System 
Normal Aging Schizophrenia Antipsychotics 
Cardiovascular 
• Increased risk of 
morbidity, MI, CAD 
• Increased risk of 
morbidity, MI, CAD 
• Increased risk of 
morbidity, MI, CAD 
• Decreased blood to 
brain, kidneys 
• Decreased diameter 
of vessels 
  
•Increased blood pressure •Increased blood 
pressure 
 
• Increased blood 
pressure 
Hematologic 
  • Increased risk of 
hyperlipidemia 
 
• Increased risk of 
dyslipidemia 
  • Increased glucose, 
A1C 
• Increased glucose, 
A1C 
  • Increased 
prolactinemia 
 
 
• Increased 
prolactinemia 
Respiratory 
• Less sensitive to 
hypoxemia, increased risk 
of respiratory failure, 
nocturnal hypoxemia, and 
decreased vital capacity 
• Decreased lung 
capacity and increased 
respiratory problems 
• Increased risk 
pneumonia 
(hypoventilation, 
dehydration, sedation) 
Gastrointestinal 
  • Increased BMI & 
central adiposity 
• Weight gain 
• Decreased saliva, taste  • Decreased saliva • Decreased saliva 
• Increased dental 
problems with loss of 
teeth 
  • Increased dental 
caries, ulcerated gums 
and buccal mucosa 
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• Decreased colonic 
muscle tone and motor 
function 
 
  • Constipation 
Urinary 
• Decreased bladder 
capacity and residual 
urine, with increased 
nocturnal frequency 
 • Dysuria, bladder 
distention and retention 
Endocrine 
• Increased insulin 
resistance 
• Increased risk of DM • Increased risk of DM, 
DKA & hyperosmolar 
syndrome (HHS) 
Neurological 
• Cognitive impairment 
with anticholinergic 
effects of meds 
• Progressive mild 
cognitive impairment, 
impaired 
neurotransmitters of 
cognition 
• Cognitive, affective 
and negative 
symptoms, cognitive 
blunting 
• Decreased energy 
production, blood flow, 
and glucose consumed 
• Impaired glucose 
metabolism—
especially in the frontal 
lobe 
  
• Decrease in dopamine 
and dopamine receptors 
• Increased dopamine 
content or metabolism 
• Limited dopamine 
neurons that can be 
activated 
• Decreased dopamine 
with D2RA & SDA  
•Prevention of 
dopamine from binding 
to D2 receptors 
• Reduced brain size 
density 
• Reduced brain 
density 
• Reduced brain size 
Immune 
• Reduced 
antibody/antigen   
response 
• Reduced immune 
response 
• Reduced immune cell 
response 
• Reduced thymic 
hormones 
• Increased C-reactive 
protein and O2 stress 
markers 
• Increased pro-
inflammatory response 
Musculoskeletal 
• Increased risk of 
osteoporosis 
• Increased risk of 
osteoporosis 
• Increased risk of 
osteoporosis 
Reproductive 
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• Decreased libido • Decreased libido • Decreased libido 
 
Metabolic Syndrome 
Metabolic Syndrome (MetS) is a metabolic disturbance formed from a cluster of 
problems including hypertension, insulin resistance, dyslipidemia, and obesity.  If left 
unchecked, MetS can increase a patient’s risk for cardiovascular disease and diabetes 
(Alberti et al., 2006).  For an older patient with schizophrenia these risks are compounded 
when poor nutritional food choices and budget constraints contribute to unhealthy diets. 
Immune System Depression 
Aging impacts the antigen/antibody system and the body’s speed of response to 
invading organisms. The age-influenced reduction in thymic activity, depression of 
immune cell response, and humeral response are all influencing factors (Solana, Pawelec, 
& Tarazona, 2006).  Elevated levels of prolactin in the body have both direct and indirect 
impact on various pathological states as indicated by the prevalence of osteoporosis, 
depressed immune response, increased cardiac events, and decreased libido.   Having a 
depressed immune system slowing the body’s ability to mount an immune response can 
also have detrimental effects. 
Increased Risk of Respiratory Disease 
Medical practitioners should be aware that this population is at greater risk of 
respiratory disease and respiratory failure.  This results from several factors. 
Polysubstance use and difficulty sleeping may predispose the older patient to use more 
sedating agents or anticholinergic agents at night.  Anticholinergic drugs or antipsychotic 
drugs also cause serious side effects such as cognitive impairment (Lieberman, 2004) and 
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block the muscarinic cholinergic receptors in the brain. This dries the mucous membranes 
and further depresses respirations.  These factors would be particularly harmful if a 
patient had a pre-existing condition such as asthma or COPD.   
Cognitive Impairment 
Aging, the history of schizophrenia, and the use of antipsychotic medications all 
effect cognition.  Impairment of cognition impacts quality of life and the patient’s ability 
to live alone.  Some antipsychotic medications exert more influence over the negative 
symptoms of schizophrenia while other medications induce cognitive blunting.  Studies 
indicate chronically institutionalized patients have a greater than average cognitive 
decline and conversion to dementia (Jeste et al., 2011).  Practitioners should be aware 
that efforts to help the patient maintain a community-based existence might counter 
cognitive decline.   
Cardiovascular Disease 
Cardiovascular disease (CVD) and increased risk of MI are found in the older 
population as well as the patients with schizophrenia.  According to Hennekens, 
Hennekens, Hollar, and Casey (2005), CVD was the explanation for excess mortality 
among people with schizophrenia.  Aging, antipsychotic medications, and disease all 
have major influence on the condition of the heart and cardiovascular system.  Lifestyle 
factors also influence those predisposed towards CVD.  Substance abuse, diets high in 
fats and of low nutritional quality, and non-compliance with prescribed medications for 
treating dyslipidemia and hyperglycemia can all impact cardiovascular health in this 
patient population.   
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Summary 
 The older patient with schizophrenia experiences challenges associated with the 
cumulative effects of an aging body, the disorder and medication use.  As the 
demographic shift occurs along with the increasing concern about comorbidity, and 
mortality associated with antipsychotic use, a need to understand and maintain wellness 
becomes evident.  To minimize drug exposure while balancing the positive and negative 
symptoms with least side effects is a major goal.  Keeping a careful eye on the aging 
body, with all the alterations of the many years of living, becomes a complicated task.  
Health problems pinpointed in this chapter’s tables were target specific for this 
population based on age, schizophrenia, and exposure to antipsychotic medications.    
 Awareness of the major health problems identified in this population provides 
insight for practitioners regarding areas needing attention. Issues related to metabolic 
syndrome (MetS), immune system depression, increased risk of respiratory disease, 
cognitive impairment, and cardiovascular disease will be examined in detail using 
evidence-based tables for graded research in these areas to determine best practice 
recommendations for optimum care.  
 Chapter 3 provides the results of a literature search of these areas as they apply to 
the treatment of older adults with schizophrenia.  The focus will be medication and 
changes in medication management because of drug actions and side effects, 
comorbidities, and physiological changes due to disease and age.  
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Chapter 3 Search Process 
 With the number of older adults schizophrenia increasing, practitioners face a 
very complex situation for the context of care and action and side effects of drugs. This 
evidence-based project’s focus is safe and effective medication management for the aging 
population with schizophrenia. 
Methodology 
 An evidence review was completed to address the PICOT question, “In 
community dwelling older adults with schizophrenia, what is the best practice for 
antipsychotic medication management?”  The following sections describe the 
components of the evidence review approach including: (a) description of evidence 
sources; (b) search terms; (c) inclusion/exclusion criteria, and (d) search process. 
Description of Evidence Source 
 A total of eight sources was searched: Cochrane Database of Systematic Reviews 
(CDSR), National Guideline Clearinghouse (NGC) through the Agency for Healthcare 
Research and Quality (AHRQ), U.S. National Library of Medicine via National Institute 
of Health, Public Medicine (PUBMED), Cumulative Index of Nursing and Allied Health 
Literature (CINAHL), Joanna Briggs Institute, Dissertations & Thesis: Full Text 
database, PsycARTICLES, PsycINFO, and MedlinePlus (OVID).  The current analytical 
framework began with identification of the systematic reviews on the topics in 
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current research.  The search was then narrowed to focus more specifically on the articles 
examining the select topics.   
 The search began with CDSR because it offers systematic reviews including 
medical and pharmacological data on many relevant healthcare issues (Melnyk & 
Fineout-Overholt, 2005).  A systemic review is a high-level overview of primary research 
on a specific question that seeks to answer that question by identifying, selecting, 
synthesizing, and appraising quality research evidence relevant to the question 
(“Evidence-based,” 2013).  The key characteristics of the Cochrane review are (a) 
utilization of clearly stated objectives with pre-defined eligibility criteria for studies; (b) 
methodology that is explicit and reproducible; (c) search criteria that attempts to identify 
all eligible criteria; (d) findings assessed for validity including bias, and (e) synthesis and 
systematic presentation of the characteristics and findings of the included studies 
(Higgins & Green, 2011).  Systematic reviews of randomized clinical trials (RCTs) are 
considered Level I evidence and are found at the top of the hierarchy of evidence with the 
most rigorous approach to the minimization of bias (Melnyk & Fine-Overholt, 2005).  
Focusing on the current PICOT question, this exploration process began with a search for 
a systematic review of RCTs in medication management for older populations with 
schizophrenia.    
 The second database searched was NGC via AHRQ.  This is an evidence-based 
guideline clearinghouse for clinical practice with quality measures.  The mission of the 
AHRQ is to improve the quality, safety, efficiency, and effectiveness of health care for 
all Americans (“Mission,” 2014).  The agency is a division of the U.S. Department of 
Health and Human Services. The NGC supports a clearinghouse for links to full 
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guidelines on specific health subjects (“About,” n.d.).  This database offered superior 
evidence-based guidelines to provide quality outcomes for medication management for 
the treatment of older patients with schizophrenia when searched utilizing the PICOT 
criteria.  
 The third search was of PUBMED because of the large, electronic biomedical 
bibliographical records this site offers.  PUBMED comprises more than 22 million 
citations for biological and medical literature for MedlinePlus, life science journals, and 
online books (“PubMed help,” n.d.).  The United States National Library of Medicine 
(NLM) at the National Institutes of Health maintains the database with the latest 
information from the world of public medicine (“Fact Sheet,” n.d.).  The PICOT question 
prompted search of this site for peer reviewed, scholarly journals providing a valid, 
unbiased meta-analysis or research, giving insight to medication management for the 
older schizophrenic population to provide best-practice clinical care.   
The fourth database in the search process was CINAHL, a large database for 
nursing and allied health information.  Records include comprehensive research indexes 
with documents dating back to 1937 including 1,637 peer-reviewed journals in the 
CINAHL database (“Full text,” n.d.).  Melnyk and Fineout-Overholt (2005) consider 
CINAHL a renowned source of comprehensive healthcare and scientific data.  
CINAHL’s focus is nursing and allied health including overviews of diseases and 
conditions with outlines of the most effective options for treatment relevant to the older 
patients with schizophrenia. 
 The fifth source searched was the Joanna Briggs Institute, Dissertations & Theses: 
Full Text database.  This is a non-profit, international research and development 
 68  
organization that collaborates with over 70 entities across the world to promote and 
support the synthesis, transfer, and utilization of evidence to improve healthcare 
throughout the world (“About us,” n.d.).  The site was searched to locate research into 
schizophrenia in older adults and related focal areas of concern related to medication 
management.   
 The sixth and seventh sources of data searched were PsychINFO and 
PsycARTICLES.  These bibliographic databases index scholarly literature in behavioral 
sciences and mental health with a psychiatric, neuroscience, and nursing focus (Melnyk 
& Fineout-Overholt, 2005). The American Psychological Association supports both sites.   
PsycINFO has more than 3.4 million records for peer-reviewed journals, books, and 
dissertations (PsycINFO, n.d.).  PsycARTICLES is a database of full text articles from 90 
landmark journals in behavioral science as well as nursing and neuroscience. All are 
peer-reviewed, top psychology and social science journals (“PsycARTICLES,” n.d.).  
Both sites offered timely research on the older population with schizophrenia including 
medication management, drug studies, and recommendations for clinical practice.   
 The eighth database searched was MedlinePlus using OVID search technology. 
MedlinePlus is the National Institutes of Health web site, produced by the National 
Library of Medicine, the world’s largest medical library (“About MedlinePlus,” 2013).  
OVID offers journal articles in life sciences with a concentration on biomedicine.  
Tailoring the OVID search criteria facilitated a focused search for schizophrenia in the 
older population with six selected journals using the medical subject headings (MeSH) 
(“Overview,” n.d.). The goal was to target any relevant articles that enhanced the 
biological and medical knowledge base of the project.  
 69  
Search Terms 
Key terms used in the search were schizophrenia, older adult, antipsychotic 
medication, side effects, comorbidities, and community dwelling.  These were important 
because of their link to the PICOT question.  Older adults with schizophrenia living in 
their communities were the specific population of interest.  Records were further grouped 
by searching via intervention, specifically medication management for schizophrenia, as 
identified in the PICOT.  Changes in medication management because of drug actions 
and side effects, comorbidities, and physiological changes dues to disease and age were 
identified while reviewing the articles of interest.  Additionally, metabolic syndrome, 
cardiovascular disease, cognitive impairment, immune system depression, and increased 
risk of respiratory disease as they related to medication management were added to 
further narrow the focus.  The outcome of this thorough search of the available research 
provides practitioners with evidence-based recommendations for the safe and effective 
medication management of this specific population of interest.   
Inclusion/Exclusion Criteria 
 The inclusion/exclusion criteria (see Table 3.1) were based on the PICOT 
question for the evidence-based project.  The terms used in the search included 
antipsychotic medications, pharmacotherapy, side effects, elderly, and physiological 
complications. Physiological complications included metabolic syndrome, cardiovascular 
disease, cognitive impairment, increased risk of respiratory diseases, and immune system 
depression.  Evidence that qualified for inclusion targeted these criteria for clinical  
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Table 3.1  
Inclusion/Exclusion Criteria 
Inclusions Exclusions 
adult population 65 years +                                      
elderly and older (aging)   
male and female 
chronic schizophrenia      
peer review journals                                                  
scholarly journals                                 
antipsychotic medications                                         
side effects  
pharmacotherapy  
1999 to 2013 (except landmark)                                                   
comorbid disease occurrences 
physiological implications 
     metabolic syndrome 
     cardiovascular disease 
     cognitive impairment                                       
     respiratory diseases 
     immune system depression  
schizotypal 
diagnostic interventions 
non-English language 
acute schizophrenia 
ECT
children 
adolescent 
early adulthood 
middle adulthood (considered) 
 
practice.  Inclusion focused on the older population (65 years and older).  Individuals 
with chronic schizophrenia were the target population as they had the most exposure over 
time to the medications and accumulation of comorbidities.  Acute schizophrenia was 
therefore eliminated.  Institutionalized patients were excluded, as the focus is on those 
living within the community not in nursing homes.  The search was limited to peer-
reviewed publications.  A ten-year period of time was selected for the most up-to-date 
information with exceptions made for landmark or classic data.  An exclusion for 
schizotypal was related to the disorder’s classification as a personality disorder that may 
be treated with therapy or other means.  Diagnostic interventions and electroconvulsive 
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therapy (ECT) were also excluded, as those topics were not a focus of this project.  
Finally, children, adolescent, and early adulthood were also barred from the search as the 
focus was on the older population. However, records that directly addressed the PICOT 
terms that provided quality data and interventions for recommendations using a middle 
adulthood group were considered for inclusion.  Although these studies were not 
exclusively focused on the elderly population, the data could be extrapolated to draw 
inferential conclusions potentially applicable to the target population.  
Search Process Description  
 In identifying relevant research studies unrelated documents were eliminated 
using a Boolean search strategy, which combines terms together in a logical, concise 
manner using inclusion or exclusion.  The initial search utilized the most expansive term 
— schizophrenia —combined with PICOT terminology of older adult, community 
dwelling, and medication management.   
 Once the initial search was completed, the inclusion/exclusion criteria were 
utilized to focus the search for a more targeted list of record results.  Each topic was 
searched separately as a subheading with the main topics remaining schizophrenia, older 
community dwelling, and antipsychotic medication management. The additional 
comorbid disease occurrences were added to the database of search criteria. The 
summary from evidence sources is summarized in Table 3.2.  
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Table 3.2  
Search Process Summary 
Evidence Search Terms Results Number 
Retained 
Cochrane Schizophrenia + 
antipsychotic 
medications + older 
adult 
 
47 records:   
Records for this search 
addressed multiple drug 
studies that were 
inconclusive, short term and 
not robust for 
recommendations. Subjects 
were young adults, or subject 
matter was excluded topics of 
this project.   
 
2 
National Guideline 
Clearinghouse 
(NGC) 
via Agency for 
Healthcare Research 
and Quality 
(AHRQ) 
Schizophrenia + 
older adults + 
antipsychotic 
medication 
management 
 
+ Schizophrenia  
20 records:   
Records excluded:  
occupational therapy, 
substance abuse, depression, 
hepatitis, autism, pathways to 
care, health lifestyle for 
young adults, and Veterans 
guides.  
     
 
0 
PUBMED Schizophrenia + 
older adult + 
antipsychotic 
medication (Table 
3.1 criteria applied) 
334 records found:   
Exclusions:  drug 
comparatives, poorly 
designed research, pregnancy, 
autism, glutamate studies, 
genetics, animal studies, 
editorial, depression, quality 
of life, alcohol and drug 
abuse, social rehabilitation, 
suicide, first psychotic break, 
global representation and 
perspective.  
7 
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CINAHL Schizophrenia + 
older adult + 
antipsychotic 
medication (Table 
3.1 criteria applied) 
618 records found:   
Exclusions:  depression, acute 
psychosis, poorly designed 
research, clinical attitudes, 
animal studies, stigma, 
substance abuse in younger 
age, psychosocial and quality 
of life issues, negative and 
positive symptoms, religion, 
editorials, nursing home 
residents and financial aspects 
of schizophrenia.  
29 duplicate or repeat articles 
1 
Joanna Briggs 
Institute 
Schizophrenia + 
older adult + 
antipsychotic 
medication (Table 
3.1 criteria applied) 
11 records found:   
Exclusions:  hospitalization, 
younger adult articles, clinic 
attendance and alternative 
therapies  
0 
PsycARTICLES Schizophrenia + 
older adult + 
antipsychotic 
medication (Table 
3.1 criteria applied) 
65 records found:   
Exclusions:  counseling 
technique (CBT, DBT), 
religion, family therapy, 
coping, school-based issues. 
0 
PsycINFO Schizophrenia + 
older adult + 
antipsychotic 
medication (Table 
3.1 criteria applied) 
44 records:   
Exclusions:  social 
rehabilitation, family therapy, 
perceptions of illness, 
concepts, cost comparisons, 
coping. 0 
MedlinePlus 
(OVID) 
Specific journals 
chosen: Acta 
Psychiatrica 
Scandinavica, 
American Journal of 
Nursing, British 
Medical Journal, 
Journal of Clinical 
Psychopharmacology, 
Journal of Nervous 
and Mental Disease, 
Schizophrenia 
Bulletin 
Schizophrenia + 
older adult + 
antipsychotic 
medication (Table 
3.1 criteria applied) 
213 records:  
Exclusions:  psychosocial and 
quality of life issues, 
editorials, poorly designed 
studies, rapid switching of 
drugs, alcohol and drug abuse 
with treatment 
recommendations, animal 
studies, stigma, first psychotic 
break, family counseling. 
Duplicates of / or repeat 
articles – 32. 
 
6 
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Summary 
 A systematic method was utilized to identify and retrieve evidence relevant to 
clinical practice to provide best practice care for medication management of community 
dwelling older adults with schizophrenia. After applying the inclusion/exclusion criteria, 
the process initially involved searching through the listing of articles one by one for the 
specific information desired.  The availability of the electronic databases, full text article 
downloads, and the consolidation of multi-journal sites of OVID helped to focus the 
search.  The evidence search resulted in a total of 16 articles and records being retained.  
The findings identified in the search will be discussed in Chapter Four. 
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Chapter 4  Evidence Synthesis 
Focusing on safe and effective medication management for the aging population 
with schizophrenia, this project’s aim was to develop an evidence table drawing on 
quality evidence and presenting conclusions for medication management.  This chapter is 
divided into four sections: Evidence Table Development, Evaluation of the Evidence, 
Analysis of Findings and Recommendations for Practice. 
Evidence Findings and Analysis 
Evidence Table Development  
 The search for articles appropriate for the EBP question and PICOT question 
identified 16 articles related to medication used with elderly patients with schizophrenia.  
The articles were entered into an evidence table using the headings: brief citations, level, 
aim, design/setting/sample, intervention, outcome, and limitations.  Mean age of the 
population was noted where possible as the target age of interest for this evidence-based 
project was 65 years and older.  
Evaluation of the Evidence  
 The articles were analyzed using the hierarchal method proposed by Melnyk and 
Fineout-Overholt (2010). The hierarchy contains seven levels with I being highest quality 
and VII lowest quality. The levels are based on the ability of the design to protect against 
threats to internal and external validity. 
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Table 4.1  
Evidence Table 
Aim 
Design/sample/ 
setting/number Outcome Limitations 
Level I 
Marriott, Neil & Waddingham (2006)/ Cochrane Collaborative 
To 
estimate 
the effects 
of anti-
psychotic 
medication 
for 
treatment 
of SZ in 
people 
over 65. 
Systematic 
review/ Three 
randomized 
clinical trials 
(RCT) 
evaluating 
antipsychotic 
drugs for SZ in 
older people 
2003-2010/ 
N=252. 
Little robust data available to 
guide clinicians to most 
appropriate drug to prescribe for 
elderly. Clinicians must 
weighing risks and benefits. 
Small sample size 
in one study; short 
duration of all 3 
studies (6-8 
weeks) limited 
results; some data 
did not define how 
randomization 
occurred; no data 
collected on global 
or social 
functioning or 
quality of life;  
Western bias to 
data noted in 2 
studies. 
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Aim 
Design/sample/ 
setting/number Outcome Limitations 
Level II 
Essali, A, Ali, G. (2013)/ Cochrane Collaborative 
To assess the 
effects of 
antipsychotic 
drugs for 
elderly 
people with 
late onset 
Schizo-
phrenia (SZ). 
Systematic 
review/ 38 
studies 
identified in the 
original 
Cochrane SZ 
Group with no 
study meeting 
criteria 
retained; 
updated 1/2/13 
with 88 studies 
identified with 
one meeting 
inclusion 
criteria, 48 are 
awaiting further 
classification. 
that compared 
antipsychotic 
drugs for the 65 
years + 
diagnosed with 
SZ. 
Treatment will be by providers 
using good clinical judgment 
and habit to guide prescribing. 
Limited data 
because only one 
study met 
inclusion criteria 
for the review to 
date. 
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Aim Design/sample/ 
setting/number 
Outcome Limitations 
Level II 
Harvey, Napolitano, Mao, & Gharabawi (2003)/CINAHL 
To compare 
effects of 
Risperidone 
and 
Olanzapine 
on 
cognition in 
elderly 
patients 
with SZ or 
Schizo 
Affective 
(SZ AFF). 
RCT / Double 
blind, 
randomized, 
parallel 8-week 
study. (Mean 
age: 71 yrs.)  
Random 
assignment to 1 
to 3 mg/day of 
Risperidone or 
5 to 20mg of 
Olanzapine 
/Recruited in 
and out patients 
/ Diagnosed 
with Sz or SZ 
AFF. /N=176. 
Low doses of Risperidone and 
Olanzapine improved cognitive 
function in elderly patients with 
SZ or SZ AFF. The 
improvements occur in aspects 
of cognitive function related to 
functional outcome. 
Results may be 
influenced by 
patients’ prior 
higher-dose First 
generation 
antipsychotics 
(FGA), which may 
affect the tested 
second-generation 
antipsychotics 
(SGAs) ability to 
enhance cognitive 
function. 
Educational levels 
of recruited by 
vary in 
multinational 
trials. 
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Aim Design/sample/ 
setting/number 
Outcome Limitations 
Level II 
Maixnew, Mellow, & Tandon, (1999)/ PUBMED 
To assess the 
efficacy, 
safety and 
tolerability of 
antipsychotics 
in the elderly. 
Literature review 
of pharmacologic, 
clinical and 
regulatory issues 
involving 
antipsychotic use 
in elderly 
patients, 
compares FGA 
and SGA, and 
make some 
general 
recommendations/ 
140 citations and 
references from 
1955 to 1999. 
FGA: Chlorpromazine - modest 
efficacy, side effects limit use. 
Thioridazine- moderate efficacy, 
side effects limit use, low EPS, 
high sedation, anticholinergic. 
Haloperidol- moderate efficacy, 
moderate side effects limit use, 
High EPS, low sedation. 
Thiothixene- insufficient, 
conflicting data. Fluphenazine- 
insufficient data                     
SGA: Clozapine - Moderate to 
good efficacy, very low EPS, 
significant side effects, Dose 
low and slowly titrate 6.25-
12.5mg/day. Risperidone- 
Moderate-good efficacy, greatest 
symptom reduction at 2mg 
(increased side effects).  Begin 
0.25– 0.5mg /day to 1-2 mg/day. 
Olanzapine - Moderate efficacy, 
more data needed. 5 to 10 mg 
best dose. Quetiapine - Moderate 
efficacy, more data needed. Low 
EPS. Begin 25mg daily. Average 
dose 100-150mg/day. Range 25-
800mg /day. Summary- SGA 
preferred due to better 
tolerability. Elderly dose at 25% 
that of young adult. Go slow, 
start low, ongoing monitoring. 
Study limited 
by the 
absence of 
data after 
1999. 
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Aim Design/sample/ 
setting/number 
Outcome Limitations 
Level II 
Ritchie et al. (2006)/ OVID 
To compare 
the efficacy 
and safety 
of 
Olanzapine 
and 
Risperidone 
in the 
treatment 
of elderly 
patients 
with SZ. 
Quantitative 
comparative 
design/Recruited 
60 yrs. + of 
outpatients in 
Australia 
between 1998 
and 2001). 
Patients 
switched from 
FGA to SGA.  
FGA had 
inadequate 
symptom 
management or 
side effects 
issues. Patients 
monitored every 
6 weeks with 
battery of testing 
to measure 
efficacy and 
safety. (Mean 
age 69.5 yrs.) 
/N=61. 
Both drugs were well tolerated, 
and their use was associated 
with fewer symptoms of SZ and 
less adverse effects. Olanzapine 
had a higher score on quality of 
life. Olanzapine (mean dose 
12.4mg/day)/ Risperidone 
(mean dose 1.97mg/day). 
Difficulty with 
recruitment 
limited the sample 
size and 
diminished power. 
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Aim 
Design/sample/ 
setting/number Outcome Limitations 
LEVEL II 
Suzuki et al. (2011)/ PUBMED 
To examine 
management 
of SZ in late 
life with 
antipsychotic 
medications 
and 
evaluated 
treatment 
resistance. 
Qualitative 
review/23 
studies included 
(8 double blind, 
15 prospective/) 
65 yrs. + 
population with 
SZ/1980 thru 
4/2011/ N=23. 
Dosing: (average) Olanzapine- 
11.7mg/day.  Risperidone- 2.4-
3.7 mg/day, (both preferred for 
treatment resistance). Clozapine 
- 53.2 mg/day. Fluphenazine-
was well-tolerated.  Mixed 
results on aripiprazole and 
quetiapine. Threshold for extra 
pyramidal symptoms (EPS) 
lower in elderly.  High 
vulnerability for metabolic 
issues due to smoking and 
lifestyle issues.  Excess 
mortality due to cardiovascular, 
respiratory as well as suicide. 
Caution with Clozapine and 
anticholinergic burden. Little 
difference in efficacy exists 
between FGA and SGA. 
None. 
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Aim 
Design/sample/ 
setting/number Outcome Limitations 
LEVEL II 
Tzimos et al. (2008)/ PUBMED 
To evaluate 
safety and 
tolerability 
of 
Paliperidone 
extended 
release (ER) 
tablets in 
elderly with 
SZ. 
RCT/ Recruited 
outpatients 
sample were 
screened to 
meet criteria 
(Mean age 70 
yrs.)/Multi-
center 
international 6 
week, double 
blind 
prospective 
study, with 
open label 
extension to 30 
weeks/N=114. 
Treatment over 30 days was 
generally well tolerated and 
may improve severity of 
symptoms of SZ. Elevated 
prolactin level in one-half 
patients. Paliperidone ER 3-
12mg/day. 
This study was 
primarily 
designed to obtain 
safety and 
tolerability data in 
an elderly 
population for 
special 
populations’ 
guidelines and 
was not powered 
for statistical 
significance. The 
data was 
consistent with 
efficacy results for 
similar study in 
younger age group 
and was 
generalized by 
this study utilizing 
the flexible dosing 
design for this 
population. 
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Aim 
Design/sample/ 
setting/number Outcome Limitations 
LEVEL III 
Ciudad, Montes, Olivares, & Gomez (2004)/ PUBMED 
To 
evaluate 
the safety 
and 
tolerability 
of 
Olanzapine 
in an open 
comparison 
in parallel 
groups that 
compared 
other SGA 
in 
treatment 
with 
outpatients 
in the 
treatment 
of elderly 
patients 
with SZ. 
Observational 
prospective, 
pharmaco- 
epidemiologic 
naturalistic 
study/ SZ 
outpatients. ≥60 
yrs. of age 
(Mean age 65.8 
±5.9 yrs.)/from 
EFESO study 
in Spain/ 
/N=135. 
Olanzapine has a favorable 
patient profile in treatment-
emergent adverse in elderly, less 
probability of resistance to 
treatment, increase global 
functioning and improved 
clinical severity. Mean dose of 
Olanzapine was 11.7mg/day.  
The combined use of two or 
more antipsychotic drugs to 
maximize treatment response is 
frequent in daily practice. Less 
anticholinergic drugs were used 
as an adjunctive medication. 
Somnolence and weight gain 
were the top two side effects 
found exceeding 10%. 
Small size of the 
control group, no 
randomization, 
post hoc sample 
from parent study, 
concomitant 
medications may 
have affected 
outcomes. 
Statistical 
significance was 
not achieved due 
to small size of the 
control group. 
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Aim 
Design/sample/ 
setting/number Outcome Limitations 
LEVEL III 
Davidson et al. (2000)/ PUBMED 
To assess 
the effects 
of 
Risperidone 
in elderly, 
chronically 
psychotic 
patients for 
12 months. 
Quasi-
experimental 
/Multicenter, 
open label of 
elderly patients 
(65yrs +), 
median age: 72 
yrs.,with SZ or 
other psychotic 
disorder (0.5mg 
2 times a day, 
beginning dose 
titration, could 
be increased to 
1.5mg to 4 mg 
2 times a day) 
/N=180 
Long-term treatment was found 
to continue both positive and 
negative symptom 
improvement, decrease in the 
severity of pre-existing 
symptoms of EPS, improved 
Cognitive Global Impression 
(CGI), and a low incidence 
tardive dyskinesia. Average 
dose 3.7mg/day. 
Lack of 
randomization 
decreased the 
power of the 
results.  
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Aim 
Design/sample/ 
setting/number Outcome Limitations 
LEVEL III 
Jaskiw, Thyrum, Fuller, Arvamitis, & Yeh (2004)/PUBMED 
To assess the 
pharmacokinetics 
and tolerability 
of quetiapine in 
elderly patients 
with selected 
psychotic 
disorder. 
Quasi-
experimental 
/Patients 
recruited from 
multicenter in 
four states age 
> 65 yrs. of age 
(Mean age 71.8 
yrs.)./an open 
label Diagnosis 
of Sz, SZ AFF, 
or Bipolar, 
rising multiple 
dose trial. 
Increased 
dosing in fixed 
step-wise 
progression 
reaching max of 
250mg, 3 times 
on day 21. 
Total days of 
testing 27. 
Investigators 
could halt 
progression for 
2 days if 
intolerant./ 
/N=12 
Pharmacokinetics of 
quetiapine were identified as 
linear. Side effects included 
postural hypotension, 
tachycardia and dizziness. 
No QT changes observed.  
The effective dose should be 
introduced at a lower dose 
and titrated at a relatively 
slower rate in patients >65 
yrs. old. 
Trial limited by 
the small 
number of 
patients, lack of 
a control group, 
the open label 
design. 
 
 86  
 
Aim 
Design/sample/ 
setting/number Outcome Limitations 
LEVEL VI 
Barak & Aizenberg (2003)/ OVID 
To assess the 
effects of 
Olanzapine 
on lipid 
abnormalities 
in elderly 
psychotic 
patients. 
Prospective 
quantitative /  
elderly 
inpatients  
(Mean age 71.7 
± 8.2 yrs.), SZ 
AFF or SZ 
exposed to 
Olanzapine  
(mean dosage 
12.9mg/day)/6 
month 
(minimum) 
Mean duration 
of treatment,  
289 days, with 
follow up / 
Israel/N=21 
No significant change from 
baseline serum lipid levels was 
found for triglycerides or 
cholesterol.  No weight gain 
was recorded.  The association 
of olanzapine exposure and 
lipid abnormalities may not 
hold true for older patients. 
Small size may 
have decreased 
the power of the 
results. 
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Aim 
Design/sample/ 
setting/number Outcome Limitations 
LEVEL VI 
Barak, Shamir, & Weizman (2002)/OVID 
To assess if 
switching 
from a 
typical 
antipsychotic 
to 
Risperidone 
would be 
beneficial 
for elderly 
SZ patients 
Naturalistic 
retrospective 
study/ elderly 
inpatients 
(Mean age 72.7 
yrs.), followed 
for 18 months 
with SZ or SZ 
AFF in Israel.  
Treated with 
either 
Risperidone or 
FGA 
(haloperidol, 
chlorpromazine, 
perphernazine, 
or 4 other FGA 
not used in the 
US)   /Low 
doses of 
Risperidone 
were used 
(mean 2.3mg)  
/N=51 
Patients in both groups had 
improved Positive and Negative 
Symptom Scale (PANSS) 
scores. Risperidone - CGI 
scores reached significance at 
18 months of the test and 
antiparkinsonian meds were 
used less frequently.  Fewer 
side effects. Basal Metabolic 
Index was higher, but did not 
reach statistical significance. 
Side effects causing 
discontinuation-FGA - EPS (1) 
-Needed more anticholinergics.                    
SGA- Lack of efficacy (2) 
Needed more sedatives to sleep. 
Naturalistic 
setting of the 
study including 
non-random 
distribution, pre-
selection of 
patients and non-
uniform treatment 
conditions may 
affect the 
outcome. There 
was no washout 
period, high use 
of concurrent 
medications and 
possible inclusion 
of treatment 
resistant patients. 
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Aim 
Design/sample/ 
setting/number Outcome Limitations 
LEVEL VI 
Finkel et al. (2009)/ PUBMED 
To examine 
metabolic 
side effects 
of yearlong 
treatment 
with 
Clozapine, 
Risperi-
done, 
Quetiapine 
or 
Olanzapine 
in 
comparison 
to treatment 
with 
Haloperidol 
or 
Perphenazine 
among 
elderly 
individuals 
with SZ. 
A retrospective 
chart review/ 
clinical records 
of psychiatric 
inpatients with 
chronic SZ, 
(Mean 
age:FGA- 
74.5yrs.SGA- 
73.8.yrs.)  
/Duration of 12 
months/ in 
Israel /N=228 
Elderly patients may be less 
susceptible to the MetS side 
effects associated with SGA 
agents than younger patient’s 
populations. 
Broad exclusion 
criteria limited 
generalization of 
results. 
Combinations of 
drug classes were 
not screened. 
Questionable too 
old for study 
sample at 74 yrs. 
old. Bias results. 
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Aim 
Design/sample/ 
setting/number Outcome Limitations 
LEVEL VII 
Alexopoulos, Streim, Carpenter, & Docherty (2004)/ OVID 
To examine 
an expert 
opinion 
survey on 
antipsychotic 
use in older 
patients with 
psychiatric 
disorders 
(SZ, 
delirium, 
dementia, 
psychosis 
mood 
disorder) 
Literature review and 
expert opinion with 
guidelines for 
recommendations/survey 
sent to geriatric 
psychiatrists, geriatric 
internists/47 question 
survey with 1411 
options / N=48. 
Consensus reached in 
78% with 92% 
completion of survey. SZ- 
recommendations: 
Preferred Risperidone- 
1.25-3.5mg/day or 
Quetiapine-100 to 
300mg/day or Olanzapine 
-7.5 to 15mg/day or 
Aripiprazole -15 to 30 
mg. /day. If the patient 
with SZ has responded 
well to treatment, the 
experts recommend 
reducing to the lowest 
effective dose and 
continuing treatment 
indefinitely. For cognitive 
impairment- preferred 
Risperidone. For diabetes, 
prefer Quetiapine or 
Aripiprazole. 
None. 
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Aim 
Design/sample/ 
setting/number Outcome Limitations 
LEVEL VII 
Kohen, Lester, & Lam (2010)/ OVID 
To explore 
Aripiprazole 
treatments 
for the 
elderly: 
efficacy and 
safety. 
Expert opinion/ 
/Neuropsychiatric 
Disease and 
Treatment/ SZ or 
SZ Aff/ 62 to 
85yrs. old/ N=10  
7 of 10 responded, 4 with 
positive symptoms, 3 with 
positive and negative 
symptoms. Less EPS  and pre- 
existing EPS decreased.  With 
less antiparkinsonian meds. 
Less sedation, weight gain, 
anticholinergic effects, and no 
QT prolongation. Improved  
CGI scales at discharge. 
None. 
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Aim 
Design/sample/ 
setting/number Outcome Limitations 
LEVEL VII 
Rado & Janicak (2012)/ OVID 
To examine the 
pharmacological 
and clinical 
profile of new 
SGA 
antipsychotic, 
Paliperidone, 
Iloperidone 
Asenapine, 
Lurasidone for 
older patients. 
Case report /A 
review of 
current data of 
new SGA  
/Examines 
current trials 
involving these 
new drugs/  65 
yr. + patients 
with 
schizophrenia 
In younger adults: 
Paliperidone - useful in 
hepatic failure. Major Side 
effects: Iloperidone -
hypotension, QT 
prolongation, Asenapine– 
orthostatic hypotension. 
Somnolence, improve 
cognition, Lurasidone - 
hypotension, QT 
prolongation, cognitive 
improvement. Drugs in study 
are less likely to have 
metabolic or EKG changes. 
Limited data 
available at this 
time on these 
new SGAs use in 
this age group to 
recommend in 
this population. 
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Level I evidence is from a systematic review or meta-analysis of all relevant randomized 
controlled trials (RCT) or evidence based clinical practice guidelines based on systematic 
reviews of RCTs.  Level II is evidence obtained from at least one well-designed RCT.  
Level III is evidence from well-designed controlled trials without randomization, and 
Level IV is evidence from well designed case-controlled and cohort studies. Level V is 
evidence from systematic reviews of descriptive and qualitative studies; Level VI is 
evidence from a single descriptive and qualitative studies; Level VII is evidence from the 
opinions of authorities and/or reports of expert committees (Melnyk & Fineout-Overholt, 
2005, p. 10).  The articles were organized from highest to lowest level.  The evidence 
table (see Table 4.1) displays one Level I studies, six level II studies, three level III 
studies, three level VI studies, and three level VII studies.  No studies fell into the 
categories of Level IV or V evidence. 
Analysis of Findings 
 Level I studies. The one Level I study was a systematic review of medications 
best suited for elderly patients with schizophrenia. Marriott, Neil, and Waddingham 
(2006) reviewed three randomized controlled trials comparing thioridazine with 
remoxipride, risperidone with olanzapine, and olanzapine with haloperidol. They 
concluded that there was no robust data to support the preferential selection of any of the 
antipsychotic medications examined. The Level I study clearly indicated that there is 
little scientific evidence to guide the selection of antipsychotics, with the exception of 
olanzapine and risperidone.   
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 Level II studies.  Expanding on Marriott et al.’s (2006) systematic review, 
Suzuki et al. (2011) reviewed 23 studies, including eight RCTs, in an effort to synthesize 
evidence related to management of late-life schizophrenia using antipsychotic 
medications.  They noted that over half of the studies were limited by small sample sizes, 
and there is little robust data available to support any medications with the exception of 
olanzapine and risperidone (which was supported for use in non-treatment resistant late-
life schizophrenia). Similarly, Essali and Ali (2013) identified 88 studies pertaining to use 
of antipsychotics for elderly patients with late-onset schizophrenia. Only one RCT, 
comparing the effects of risperidone and olanzapine, met inclusion criteria. The authors 
concluded that there is no convincing evidence to support the use of any specific 
antipsychotic drug with this population.  Suzuki et al. (2011) remarked on the lack of 
evidence related to treatment resistance, antipsychotic polypharmacy, and medication 
augmentation for older patients with schizophrenia.   
 More broadly, Maixner, Mellow, and Tandon (1999) conducted an extensive 
review of the existing literature concerning pharmacologic, clinical, and regulatory issues 
related to the use of antipsychotic medications in elderly patients. They concluded that 
second generation antipsychotics (SGA), in general, had a favorable side effect profile 
compared to first generation antipsychotics (FGA) because of the lower association with 
extrapyramidal symptoms (EPS), but noted the paucity of scientific data to document the 
efficacy and safety of antipsychotic medications for older adults, despite the frequency of 
their use. The authors reviewed literature dating from 1955 through 1999, which is a 
limitation in that more recent literature is not included.  
 94  
 Ritchie et al. (2006) examined the efficacy and safety of olanzapine and 
risperidone utilizing a sample size of 61 elderly patients with schizophrenia. Criteria for 
inclusion included having completed a previous crossover study in which patients 
switched from FGA to a SGA, and having experienced imperfect symptom control or 
troublesome side effects while prescribed the FGA.  During the comparative six-month 
study, patients in the olanzapine and risperidone groups were assessed every six weeks. 
The following rating instruments were used for monitoring: the Brief Psychiatric Rating 
Scale; The Scale for the Assessment of Negative Symptoms; the Montgomery Asberg 
Depression Rating Scale; the Mini-Mental State Examination; the Abnormal Involuntary 
Movement Scale; the Barnes Akathisia Rating Scale; the Simpson Angus Scale; World 
Health Organization Quality of Life instrument-brief.  The study was limited by the 
difficulty with recruitment, as many of the potential participants were already on 
risperidone or olanzapine, and clinicians were reluctant to change patients’ current 
medications.  This reduced the available participant pool to less than 80 patient subjects, 
decreasing the statistical power of the study.  Additionally, cost concerns prevented the 
use of a double blind study design.  Results indicated that both drugs were well tolerated 
and effective in reducing symptoms of schizophrenia with few side effects as compared 
to FGA.  Participants on olanzapine scored higher on a quality of life measure than 
participants on risperidone. Patients switched to risperidone or olanzapine from FGA 
improvements cannot exclude that the change in class of drugs and a reduction in dose 
over time were the causative factors of improvement. The authors also noted a lack of 
high quality evidence regarding use of antipsychotic medication in elderly patients with 
schizophrenia.    
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 Harvey, Napolitano, Mao, and Gharabawi (2003) also examined the effects of 
risperidone and olanzapine on cognition in a RCT involving 176 elderly patients with 
schizophrenia or schizoaffective disorder over an eight-week period. Participants on both 
drugs showed significant improvement in cognitive functioning at low doses. This study 
concluded with the recommendation of longer studies for future research. 
 Tzimos et al. (2008) conducted a six-week RCT that examined the safety and 
tolerability of oral paliperidone extended release (ER) in 114 elderly patients with 
schizophrenia.  A screening phase consisting of up to a five-day washout period 
proceeded the six-week double blind phase. To ensure patient safety during this study, 
patients were hospitalized from the first day of the double blind phase for at least 14 days 
for monitoring.  The eligible patients were then randomized 2:1 to receive a flexibly 
dosed paliperidone ER or placebo once daily.  Starting dose was 6mg a day.  Doses 
adjustments were increased weekly by 3mg increments, but decreased dosing could be 
made at any time.  Safeties of adverse events were measured using The Medical 
Dictionary for Regulatory Activities Terminology Version 8.1, IFMPA, and Geneva, 
Switzerland.  Movement disorders rating scales, Simpson Angus Scale, Barnes Akathisia 
Rating Scale and Abnormal Involuntary Movement Scale were used throughout the 
double blind and open label phases of the study. The efficacy of paliperidone was 
measured with Positive and Negative Symptom Scale, Clinical Global Impressions Scale 
Severity Score.  Personal and Social Performance Scale, and Schizophrenia Quality of 
Life Scale were used in examining the efficacy of paliperidone on the patients’ 
perception of function, mood, and life.  Clinical laboratory collection to monitor 
metabolic data and body parameters included routine tests, plus serum prolactin, C-
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peptide and insulin, vital signs, body measurement, body weight, and 12-lead EKG.   Of 
the 38 patients in the original placebo group, 26 (68%) completed the six-week double 
blind phase trial, and 64 of 76 (84%) of the paliperidone patients completed the study.  
The study further offered an optional 24-week open-label extension in which 88 patients 
continued.  Paliperidone ER treatment was found to be well tolerated and may improve 
symptom severity in elderly patients with schizophrenia.  Prolactin levels were elevated 
in one-half of patients.  No adverse events were reported of any cardiovascular or QT 
prolongation. Two patients with glucose-related issues and three patients with significant 
weight increase were reported as experiencing adverse events. The authors further noted 
the scarcity of data for treatment of schizophrenia in the elderly population, commenting 
that only a handful of published studies have assessed tolerability of an SGA longer than 
three months in duration. At least two design flaws must be considered in interpreting 
and generalizing the results of this study.  Due to small sample size, the study may not 
have had enough power to determine significant group differences, and the short time 
frame (six weeks) may also not be enough time for differences to manifest themselves. 
 In summary, Level II criteria provided five FGA and six SGA for examination 
within six studies.  Level II studies favored SGA for the elderly population for positive 
and negative symptom management as well as positive effects on cognitive, and quality 
of life outcomes. Compared to the safety profile of FGA, these medications were less 
likely to be associated with the occurrence of EPS.  Risperidone and olanzapine were the 
most frequently examined medications, which could be due to their longevity on the 
market.  Prolactin level elevation was observed in patients medicated with paliperidone.  
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A lack of high quality studies in the elderly patient population that meet level II criteria 
especially any of long duration was notable.   
 Level III studies.  Three Level III studies were identified.  Each well-designed, 
controlled trial examined a different SGA in elderly patients with a psychotic disorder.  
Ciudad, Montes, Olivares, and Gomez (2004) compared the safety and tolerability of 
olanzapine to other antipsychotics with 135 elderly outpatients over 60 years of age. 
Participants were non-randomly assigned to two groups. One hundred and five patients 
were assigned to the olanzapine group and 30 to the comparison group. Half of those in 
the control group received risperidone, and the remaining fifteen received medication 
defined as high potency or low potency FGA.  Assessment times included baseline, three 
month, and six-month assessments, as well as spontaneous assessments as deemed 
necessary by the provider during the treatment.  Assessments included screening for EPS 
using the Udvalg for Kliniske Undersøgelser side effect rating scale, Clinical Global 
Impressions –Severity and Global Assessment of Function scales to assess patients 
clinical status and effectiveness of medications.  The Awad scale assessed the patients’ 
attitude regarding medications. Quality of life was measured using the EuroQol that 
assess health state in five dimensions:  mobility, personal care, daily activities, 
pain/discomfort and anxiety.  No significant group differences were found which could 
be related to the small size of the control group.   Participants in the olanzapine group had 
lower akathisia, tremor, hypertonia, and higher incidence in insomnia, malaise, diarrhea 
as compared to the control group.  However, 10% had somnolence and weight gain.  
Additionally, there was a lower use of anticholinergic drugs in patients taking olanzapine.  
Olanzapine was effective in reducing the severity of symptoms and increasing global 
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function at the end of the six-month follow-up as compared to treatment with other 
antipsychotic medications, as reflected by an increase in the Global Assessment of 
Function scores and a decrease in the Clinical Global Impression-Severity scale (Ciudad, 
Montes, Olivares, & Gomez, 2007). 
 Davidson et al. (2000) conducted a yearlong study of risperidone enrolling 180 
elderly patients with schizophrenia or schizoaffective disorder. The trial focused on the 
effects of long term use of risperidone in the older population as measured by changes in 
the Positive and Negative Symptom Scale (PANSS), EPS assessment including the 
Extrapyramidal Symptom Rating Scale, and Clinical Global Scales, which were assessed 
at one, two, three, six, nine, and 12 months during the study.  A historical comparison 
group was utilized to improve the validity of the interpretation of the results. This 
comparison group with similar demographics and diagnoses of chronic schizophrenia was 
treated with FGA for one year (Davidson et al., 1995). Greater than 50% of the patients 
had both positive and negative symptom improvement at the endpoint.  Risperidone was 
well tolerated with lower incidence of tardive dyskinesia compared to participants in the 
1995 study group.  A decrease in the severity of the pre-existing EPS was observed with 
a concomitant decrease in the use of anticholinergic medications.  Cognitive 
improvements were also noted, but could not be clearly attributed to treatment with 
risperidone.  Other factors affecting cognitive outcomes may have been a reduction in use 
of anticholinergic medications, or the discontinuation of the previous antipsychotic 
medication that may have caused the decline of cognition.   
 Jaskiw, Thryum, Fuller, Arvanitis, and Yeh (2004) assessed in a 27-day study the 
tolerability of quetiapine in 12 elderly patients: eight with schizophrenia, two with 
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schizoaffective disorder, and two with bipolar disorder.  A more rapid titration of the 
medication was chosen for this study to allow a longer pharmacokinetic testing time at 
the desired dose range.  This resulted in higher incident of adverse reactions including 
postural hypotension and dizziness with a 30-50% reduction in the drug’s clearance from 
the body.  Prolactin was unaffected.  The authors found quetiapine had favorable efficacy 
and adverse effects profile in the 65 years and older population, with doses up to 250mg 
given three times a day.  This study was limited by its small sample size, uneven 
distribution of male (nine total) and female (three total) participants, and a rapid titration 
of medication.   Future recommendation for replicating this study would suggest a slower 
titration as a means of minimizing the negative side effects found in this study.  
Considering the reduction of overall hepatic and renal clearance in the elderly population 
that occurs with aging, a slower titration would be prudent. 
 In summary, Level III articles noted each of the three drugs — risperidone, 
olanzapine and quetiapine — were effective in reducing symptoms of psychosis in 
elderly patients with schizophrenia or other chronic psychotic disorder. Side effects 
included somnolence and weight gain with olanzapine, and postural hypotension or 
dizziness with quetiapine.  Researchers recommended that medications be initiated at low 
doses and titrated slowly in order to minimize side effects, keeping in mind potential 
interactions and effects of concurrent medications.  Improvement of psychosis may also 
improve cognitive and global functioning.  Caution was offered to monitor 
anticholinergic medication suggesting less use for a more positive cognitive outcome. 
 Level VI studies.  Three single descriptive or qualitative studies met criteria for 
Level VI.  Barak, Shamir and Weizman (2002) questioned whether switching from a 
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FGA to risperidone would be beneficial.  Fifty-one elderly subjects, age 65 to 88 years, 
were chosen for this study.  Twenty-five patients were treated with a FGA, including 
haloperidol, perphernazine, chlorpromazine and four other FGA not FDA approved for 
use in the US, and 25 patients were switched to risperidone with both groups monitored 
for 18 months. Both classes of medications improved Positive and Negative Symptom 
Scale scores. The results indicated switching was effective and well tolerated.  Patients 
switched to risperidone experienced improved Cognitive Global Impression Scale scores 
and a reduction in side effects from the FGA including hypersalivation, sedation, and 
apathy.  The authors noted the Basal Metabolic Index was higher in the risperidone 
group, but the difference was not statistically significant with patients noted to return to 
near baseline at the testing’s endpoint.  The incidence of EPS was higher in the FGA 
group, which resulted in a greater need for anticholinergic medications.  The risperidone 
group used more concomitant sleep aids.  This was thought to be due to the less sedating 
quality of the risperidone as compared to the FGA.  Limitations that may have affected 
outcomes included a naturalistic setting, pre-selection of patients, non-uniform treatment 
conditions, non-random assignment, no medication wash out period, high use of 
concurrent medications, and inclusion of treatment resistant patients (Barak, Shamir, & 
Weizman, 2002).  
 Barak and Aizenberg (2003) studied 21 elderly patients with schizophrenia or 
schizoaffective disorder to assess the effects of first time exposure of olanzapine on lipid 
abnormalities. The mean duration of olanzapine treatment was 289 days (SD± 139 days.  
At the end of this prospective study, no significant changes from baseline lipid levels or 
weight gain were found.  Finkel et al. (2009), in a one-year retrospective study examining 
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the metabolic side effects of clozapine, risperidone, quetiapine, olanzapine compared to 
perphernazine and haloperidol in 228 elderly patients with schizophrenia, similarly found 
no significant differences with respect to triglycerides or cholesterol levels.  Additionally, 
in examining the metabolic effects of FGA and SGA, the elderly patients’ Basal 
Metabolic Index, body weight, blood glucose, B12 and folic acid levels remained 
unaffected.  The SGA carry a class warning for weight gain, lipid abnormalities, and are 
associated with inducing the metabolic syndrome. Elderly patients may be less 
susceptible to the metabolic side effects associated with antipsychotic medications than 
younger populations. The elderly population as a group has a higher rate of chronic 
conditions including cardiovascular disease and diabetes.  Finkel et al. (2009) suggested 
the mean age of this study, 74 years, was too old to represent the elderly population with 
schizophrenia whose average lifespan is typically 65 years.  Both studies suggested 
further trials with larger, younger samples. 
 In summary, Level VI evidence suggested the elderly population might be less 
susceptible to the metabolic challenges of the SGA.  These would include cholesterol, 
triglycerides and weight gain.  Both FGA and SGA are effective in reducing Positive and 
Negative Symptoms Scale scores. More EPS occurs with use of the FGA requiring more 
anticholinergic medications.  Studies that are more extensive are needed to explore the 
metabolic and lipid changes in the elderly patients prescribed antipsychotic medication.  
 Level VII studies. Evidence from the reports of expert committees and/or opinion 
of authorities comprises Level VII, the last level of the rating system.  Three reports 
qualified for Level VII.  Alexopoulos, Streim, Carpenter, and Docherty (2004) developed 
a 47-question survey based on a literature review to assess expert opinion on 
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antipsychotic use in elderly patients with schizophrenia, delirium, dementia, delusional 
disorder, and psychotic mood disorder. Fifty-two American experts in geriatric psychiatry 
and medicine responded to the survey. The responses were used to write guidelines for 
use of antipsychotics in older patients.  Experts treating elderly patients with a diagnosis 
of schizophrenia preferred risperidone 1.23-3.5mg/day, quetiapine 100mg-300mg/day, or 
aripiprazole 15mg -30mg/day.  If the patient response was successful, the expert panel 
recommended reducing the medication to the lowest effective dose and continuing 
indefinitely.  The experts preferred risperidone for use in their elderly patients with a 
cognitive impairment when diagnosed with schizophrenia and quetiapine or aripiprazole 
for prescribing for patients with co-occurring diabetes.  
 Kohen, Lester, and Lam (2010) published a clinical article focusing on the safety 
and efficacy of aripiprazole to treat schizophrenia in patients over 60 years of age. The 
authors reviewed clinical trials with aripiprazole and elderly patients with schizophrenia, 
as well as clinical studies involving psychosis in Alzheimer’s and Parkinson’s disease, 
agitation associated with schizophrenia and bipolar disorder and the use of aripiprazole in 
the older population group. Few studies were found completed to date on this topic and 
population. Only one study within the article addressed the target population.   Ten 
elderly patients, age 62 to 85 years of age, with schizophrenia or schizoaffective disorder 
were treated with aripiprazole. Seven responded to the treatment noting improved 
Positive and Negative Symptom Scale and Clinical Global Impression score, less EPS 
from prior medications, and less anticholinergic medications required to treat side effects.  
Less weight gain and sedation were also observed.  Improvements were based on prior 
use of FGA and other SGA medications and clinical observations of patients’ behavior 
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and Clinical Global Impression Scale assigned retrospectively.  Based on prior reports, 
clinical reviews and clinical practice experience, the effective dose range utilized for 
safety and tolerability was 2 - 15mg/day for the elderly population.  The authors further 
suggested 20 minutes of exercise a day to reduce metabolic syndrome or providing 
healthy food choices if patients were unable to exercise. 
 Rado and Janicak (2012) examined case reports describing the use of the new 
SGAs for treatment of schizophrenia in elderly patients.  The authors’ goal was to 
examine these SGA because of the adverse effects profile of the FGA and the potential 
alternatives offered by the new SGA in the elderly population.  The case reports were 
obtained from an extensive internet search of MedlinePlus, references from relevant 
articles and abstracts from professional meetings. This report offered no new evidence 
beyond that already reported concerning the use of paliperidone (Tzimos et al., 2008).  
The author found no studies examining the use of luradone or iloperidone in elderly 
patients and reported one study involving asenapine (Dubovsky, Frobose, Phiri, Greef & 
Panagides, 2012).   Prior research involving non-elderly populations has indicated that 
patients treated with iloperidone, paliperidone, asenapine, and lurasidone are less likely to 
have metabolic alterations than older SGA.  Prolonged QT intervals and orthostatic 
hypotension are side effects observed with iloperidone, asenapine and paliperidone. 
Paliperidone, like risperidone, increased prolactin levels. The authors suggested 
paliperidone for patients with hepatic impairment because of the drugs predominant renal 
excretion.  Asenapine and lurasidone were noted to improve cognition as measured by 
improved Clinical Global Impression scores. These drugs need to be adjusted for renal 
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and/or hepatic impairments.   All of the new SGA have minimal research in the elderly 
population.  Further studies with adequately designed and powered studies are needed.  
 In summary, The Level VII evidence added the dimension of the newest atypical 
antipsychotic medications on the market.  Although not supported by scientific evidence, 
clinical experts noted that these newer medications may have fewer metabolic issues, and 
relatively low risk of prolactin elevations and EPS, while being effective at reducing 
psychotic symptoms. Lurasidone’s low risk for hypotension and QT prolongation with 
the potential of cognitive improvement may make it a useful agent in older people. 
Cautions regarding risks of cardiovascular side effects were drug specific. Further 
research will be needed to validate the Level VII evidence.  
Recommendations for Practice 
 Relatively few robust studies have been conducted involving antipsychotic 
treatment in elderly patients with schizophrenia.  Unfortunately, there has been little 
accumulation of new knowledge since 1999, despite the introduction of several SGA with 
unique side effect and risk profiles.  The limited research has left providers with little 
guidance as to how to proceed with psychopharmacologic treatment in this population. 
Reduced incidences of EPS and TD in SGAs have supported SGA use over FGA in all 
age groups.  There is some very preliminary evidence to suggest that SGAs are effective 
for treating symptoms of schizophrenia in older patients and may be better tolerated than 
in younger patients, with a lower incidence of metabolic issues.  Researchers and clinical 
experts recommend relying on the clinicians’ assessment and clinical reasoning skills 
until more evidence becomes available. 
General Clinical Practice Recommendations 
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 In general, providers are advised to identify the target symptoms to be treated, 
weigh the risks and benefits of all potentially appropriate medications, and use best 
clinical judgment to choose a medication based on the individual patient’s needs and 
psychological/physiological status.  Adherence is critical to successful treatment and 
positive outcomes, therefore patients and families should be included in the decision-
making process to simplify the protocol and maximize compliance. 
The following recommendations are drawn from individual studies and expert 
opinion and may only be used as data in the clinical reasoning process. 
 Recommendation 1. Perform a thorough diagnostic evaluation to include review 
of systems, physical assessment, and laboratory analysis of cardiac, hepatic, and renal 
functions prior to prescribing medications  (Maixner, Mellow, & Tandon, 1999). 
 Recommendation 2. Second-generation antipsychotics are preferred over FGA 
when choosing the best antipsychotic drug for the elderly patient  (Alexopolos, Streim, 
Carpenter, & Docherty, 2004; Finkel et al., 2009).   
Specific medication recommendations based on safety and efficacy include:  
 Risperidone is identified as the number one choice (based on safety and efficacy) 
(Alexopoulos et al., 2004; Barak, Shamir & Weizmann, 2002; Davidson et al., 2000; 
Finkel et al., 2009; Harvey, Napolitano, Mao, & Gharabawi, 2003; Maixnew et al., 1999; 
Marriott, Neil, & Waddingham, 2006; Ritchie, et al., 2006; Suzuki et al., 2011)  
  Olanzapine is the second choice (based on safety and efficacy) (Alexopolos et al., 
2004; Barak & Aizenberg, 2003; Ciudad et al., 2004; Harvey et al., 2003; Maixnew et al., 
1999; Ritchie et al., 2006; Suzuki et al., 2011). 
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 Quetiapine is the third choice (based on safety and efficacy) (Alexopolos et al. 
2004; Jaskiw, Thyrum, Fuller, Arvamitis and Yeh, 2004). 
 Aripiprazole is the fourth choice (based on safety and efficacy) 
(Alexopolos et al., 2004; Kohen, Lester & Lam, 2010). 
Recommendation 3. The dosing range suggestion is to start low (25% of young 
adult dose) and to titrate slowly with careful monitoring of side effects (Maixner et al., 
1999). 
Recommendation 4.  Avoid the use of anticholinergic medications when possible 
because of negative effects to cognition (Ciudad et al., 2004; Kohen et al., 2010; Suzuki 
et al., 2010).  
Recommendation 5. The recommended frequency of follow-up monitoring to 
evaluate antipsychotic treatment protocol is based on patient status. 
• Upon initiation of antipsychotic:  Every one to two weeks until symptomatically 
stable for one month on the same dose of antipsychotic medication. 
• Early in treatment monitor tolerability and therapeutic benefit every two to three 
months until the patient has been stable for six months on the same medication 
and dose. 
• Routine follow-up every three to six months if patient is stable and there have 
been no medication adjustments. 
• Monitor 10 days to four weeks following an antipsychotic dose change 
(Alexopoulos et al., 2004). 
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Recommendation 6. Allow two weeks to assess whether symptoms are 
adequately controlled before changing the antipsychotic dose or type of antipsychotic 
medication, as long as the patient is tolerating the medication  (Alexopoulos et al., 2004). 
Recommendation 7. Continue antipsychotic treatment indefinitely at lowest 
effective dose necessary to control symptoms of schizophrenia (Alexopoulos et al., 
2004). 
 The findings of this project will be reviewed and discussed in Chapter Five.  
Clinical implications of the evidence and recommendations for future research will also 
be addressed.  
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Chapter 5  Outcome and Implications 
 Patients dealing with mental illness encounter many lifetime hurdles within the 
mental health system.  One challenge is to find the appropriate medication to help 
manage symptoms.  Advances in psychopharmacology include the frequent introduction 
of new drugs to treat schizophrenia.  Unfortunately, the older population is not included 
in any significant trials of these new drugs.  This follows the historical pattern of minimal 
representation of older patients with schizophrenia in high quality drug studies of second 
generation antipsychotic (SGA) medication.  Despite an exhaustive literature search, only 
16 articles were found that met inclusion criteria for this project.  The majority of these 
studies examined the older drugs, especially the first few SGA medications on the market 
in the United States, in comparison with each other or with first generation antipsychotic 
(FGA) medications.  The newer drugs were mentioned as promising, but no viable 
studies to date have been conducted.  These studies provided little new insight into best 
practice for the use of antipsychotics to treat older adults with schizophrenia beyond the 
already known prescribing practices for this population.   
There are many possible reasons for this absence of data.  Recruitment of a 
sufficient number of elderly subjects to participate and follow up may be difficult.  The 
researchers may want to avoid the confounding effects of other medical conditions and 
medications.  Reluctance to involve this more delicate population may also be a concern.  
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Unfortunately, RCTs are not the ideal nor preferred method to study medication 
actions for this more sensitive population.  The pharmacokinetic and pharmacodynamic 
response to medications in the elderly population is unique and best monitored in a more 
naturalistic setting over longer time spans.  These conditions are not easily managed 
within the pharmaceutical six or eight week trial protocols preferred in most drug studies.  
There is limited access to this population as well, as community dwelling elderly people 
with schizophrenia are dependent on community resources for transportation and 
coordination of care, which results in missed medications, lab work, and appointments.  
During the search process, more studies were available examining the use of 
antipsychotic medications in the elderly with dementia. This trend may be attributed to 
better accessibility of the elderly population with dementia for participation and 
monitoring in research, as they are more likely to reside in assisted living facilities or 
nursing homes.  There is also a larger pool of patients in the dementia population versus 
the elderly population with schizophrenia from which to draw the study group.   
 To provide context for the evaluation of evidence, this project examined the 
complex intersection of normal aging processes, physiological changes associated with 
schizophrenia, and the action of antipsychotic medications to provide an overview of the 
factors providers must consider in order to safely prescribe antipsychotic medications for 
older adults with schizophrenia.  The expected cognitive and physiological changes 
associated with aging combined with comorbid conditions and polypharmacy can further 
complicate the symptom management by affecting the tolerance and efficacy of 
antipsychotics in aging patients.   Unfortunately, for the reasons noted above, although 
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the older population with schizophrenia is increasing, it is likely that high-level evidence 
to guide prescriptive practice will continue to be lacking.   
Nevertheless, awareness of the considerations outlined in the project can help 
providers evaluate the potential for newly marketed drugs to be incorporated safely into 
patients’ treatment regimens.  Further, the information presented emphasizes the 
importance of ongoing monitoring to determine the need for medication adjustment as 
individuals age and their care becomes more complex.  Proactively identifying the risks 
to health in this fragile patient population will help prevent exacerbation of comorbid 
health problems or the occurrence of complications requiring more medications and 
increasing the potential for hospitalizations.  Better overall health will allow older 
patients with schizophrenia to live independently in the community for a longer period of 
time and attain a higher quality of life.   
Healthcare System and Community Resources 
 Providers’ knowledge and skills become even more critical because of the barriers 
within the healthcare system to providing efficient care to this older population with 
chronic, severe mental illness.  From 2005 to 2010, 14% of psychiatric hospital beds 
nationwide were closed, with four states closing an estimated 50% of their inpatient 
psychiatric beds and another 13 states closing 25% of their total inpatient psychiatric 
beds (“New Treatment,” n.d.).  More and more, patients must depend on community 
mental health providers for their psychiatric care.  Due to the increasing life expectancy 
and the aging of the baby boomer generation, there will be a greater number of older 
patients with mental health disorders, including schizophrenia.  Once an elderly patient is 
established within the system, complicated insurance protocols, prior authorizations, and 
 111 
 
regulatory restrictions on prescribing can make offering a medication for symptom 
management for elderly patients a daunting task.  The Affordable Care Act (ACA) 
mandates parity for treatment of mental health and physical illness.  Unfortunately, this 
comes at a time of decreased mental health funding and fewer medical students choosing 
to enter psychiatry as a career, resulting in a lack of qualified mental health professionals 
in a time of peak need (Thomas, Ellis, Konrad, Holzer, & Morrissey, 2009).  Psychiatric 
mental health nurse practitioners (PMH-NP), as the only other mental health provider 
with prescriptive authority, have the opportunity to fill some of these gaps and make a 
powerful impact in the lives of older patients with schizophrenia for whom medication is 
an integral part of symptom management.   
 The system does try to optimize health for elderly patients with schizophrenia 
enabling them to follow through with acquiring necessary care.  Medical expenses are an 
ongoing issue. Medicare is available to this population, as are the insurance benefits of 
Medicare A and B.  Choice for Medicare D coverage for medication coverage is the 
choice of the individual, which leaves many patients questioning which plan to choose.  
Co-payments for the patients are widely variable.  Medicaid is available in some limited 
financial circumstances for additional coverage to help defray the monetary burden of 
medical care.  Some areas offer a base form of case management, but with funding cuts 
for mental health services, these are limited.  Accessing care can also be problematic.  
Transportation services are offered in some areas to help individuals with special needs, 
whether physical or psychological, but the trend has been to begin charging a fee for each 
way or per mile, which is difficult for those patients on limited income to afford.  
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Community mental health facilities are available as well but typically in larger cities and 
communities. 
 Regrettably, the weaknesses within the system for elderly patients with 
schizophrenia outweigh the strengths in meeting their needs for services and care.  
Limited access to mental health care remains a problem due to a shortage of qualified 
providers and overcrowding of the existing mental health clinics.  Funding cutbacks in 
mental health services have reduced case management to almost non-existent except for 
the most severely impaired patients.  The logistics for the patient to maneuver the mental 
health system, obtain lab work as requested, and fill out forms for insurance coverage as 
requested become overwhelming.  This population is more likely to be unmarried and 
without children, requiring more independent functioning within the community.  With 
less support to draw upon in stressful times, the elderly population with schizophrenia is 
more likely to be in need of an inpatient respite. However, with fewer hospital beds 
available and poor individual support systems, the options are limited. 
Limitations of the Project 
 This project was limited by the paucity of available quality research that included 
older adults with schizophrenia. Ultimately, it was disheartening to learn that there is not 
a lot of high-level research data available on the 65-year and older population with 
schizophrenia.  The majority of information available was anecdotal, not empirical.  Most 
empirical studies were descriptive and had limitations that resulted in few findings to 
guide practice.  Recommendations were broad and focused primarily on use of clinical 
judgment.  In order for clinical judgment to be useful, clinicians must have a clear 
understanding of the type of medications available and associated actions, risks, and side 
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effects.  Further, the clinician needs a strong awareness of each patient’s baseline status 
and health factors that might affect his or her response to antipsychotic therapy.  Almost 
every publication reviewed since 1999 concluded by calling for future research utilizing 
the older population in high quality studies.  This, however, did not occur. 
Research Implications 
 Out of the frustrations of finding so few reliable studies investigating the older 
population with schizophrenia arises opportunity.  An intriguing possibility is that the 
older population might be less susceptible to metabolic side effects than younger patients 
with schizophrenia.  Two studies indicated a lack of dyslipidemia in elderly patients 
when similar studies indicated an increase in dyslipidemia in younger patients with 
schizophrenia (Barak & Aizenberg, 2013; Finkel et al., 2009).   Additional quality 
research concerning safety profiles is needed in light of the high-risk potential of the 
metabolic syndrome and cardiovascular disease currently associated with the elderly 
population with schizophrenia.  
Second, research noted elevated prolactin levels with FGA, as well as risperidone 
and paliperidone (Tzimos et al., 2008; Table 2.2; Table 2.3). Younger patients manifest 
breast tenderness, gynecomastia, and libido issues signaling elevated prolactin.  However, 
in elderly patients these cues are muted or nonexistent.  With aging, a lower libido may 
be considered normal and not questioned.  The standard protocol for monitoring prolactin 
is to assess “for cause” when symptoms are present.  Without symptoms, these warning 
signs would go unnoticed when levels are elevated.  Hyperprolactinemia may initiate 
calcium loss.  With the higher prevalence of osteoporosis and hypocalcemia in the older 
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population, a better understanding of the impact of elevated prolactin in older age is 
important from both safety and good health standpoints.   
Third, two studies examining sleep apnea and aging (Winkelman, 2001) and 
severe obstructive sleep apnea and psychiatric patients (Martinez-Garcia et al., 2012) 
indicated a high probability of increased cardiovascular death in the target patient 
population.  Although there are no studies that measure the relationship of sleep apnea to 
antipsychotic medications, it is a potential concern because adding psychotropic 
medication can impact the depth of sleep. Studies focusing on problem areas of 
obstructive sleep apnea, respiratory issues, pneumonia, and cardiovascular issues are 
critical as respiratory issues were a high-risk area identified in the correlation Table 2.3.   
Fourth, the research most urgently needed would be pharmacology-based to 
explore safety, tolerability, and efficacy of the newest second-generation antipsychotics 
(SGA) such as iloperidone, lurasidone, asenapine, and paliperidone.  The newest SGA 
appear to have a promising profile, especially with the low affinity antagonism for 
histaminic and muscarinic receptors reducing side effects to which elderly individuals are 
particularly sensitive, including anticholinergic effects (Rado & Janicak, 2012).   
Finally, more research funding for investigation of promising new antipsychotic 
medications would be potentially beneficial.  Some medications are not yet available in 
the USA because they have not met criteria for FDA approval.  Other medications may 
have a broader research base because of the willingness of pharmaceutical companies to 
fund the studies necessary to gain approval for specific medications.  More independent 
research about the multiple types of medications available is needed to help prescribers 
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be as knowledgeable about the choices as possible to better guide decision-making for 
each individual older patient with schizophrenia.  
Practice Implications 
 With the increased knowledge base required for practice decisions, PMH-NPs 
have a major role to play in treating patients with chronic severe mental illnesses that 
persist into older age.  Keeping abreast of new treatment, medications, and treatment 
protocols with continuing education will continue to be a part of best practice 
expectations.  Maintaining records of patients’ lab work, current medications, and other 
medical conditions at each visit is a cornerstone to quality care.  Checking for TD and 
EPS as well as side effects of the antipsychotic medications at each visit must be 
included.  Coordination with other disciplines that provide case management or providing 
a holistic approach is ideal, but with funding often a problem for these services, PMH-
NPs can continue to advocate for patients as part of the best practice approach regardless 
of the circumstances.  Becoming aware of the lifestyle choices of each patient and 
guiding them towards the healthiest options will be invaluable.  Careful monitoring for 
drug-to-drug interactions or symptoms of alcohol or substance abuse to minimize harm is 
critical.  Teaching and giving feedback for concerns of the patient and challenging 
individuals to take their medication every day are important goals in helping patients 
remain out of the hospital.  Celebrating goals and achievements with the patient, as well 
as mourning losses and failures, are ways of acknowledging the patient as a person.  All 
important parts of treating the whole patient, gaining trust, making a bond, and treating 
the person must be included in care.  The patients’ families should be incorporated as 
partners in care and decision-making if possible and permitted by the patient.  With the 
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skills, training, and caring of the PMH-NP, the older patient with severe mental health 
issues can find a competent professional for one-to-one treatment.   
Policy Implications 
 The examination of literature for this project brought to light several policy 
implications related to mental health care in the US.  Foremost is the need for funding to 
improve access to care.  The Affordable Care Act (ACA) opened the door to many people 
by offering healthcare to those who were previously uninsured. While still in the early 
stages of implementation, the process was intended to be affordable and easier to 
navigate with a greater transparency of services offered.  Although Medicare covers 
elderly adults with schizophrenia, changes to required insurance coverage may affect 
access to mental health care in general. Several benefits afforded by the ACA have 
significant implications for patients with chronic severe mental illnesses including 
coverage for mental health, substance abuse, and pre-existing conditions.  The ACA 
requires that these benefits not be subject to greater restrictions or limitations than the 
plan’s medical/surgical benefits (“Do marketplace,” n.d.).  Closing the Medicare D 
“donut hole” for medications have left some with even higher copayments. While 
problems remain, PMH-NPs can use their influence to support policies that increase 
access to affordable mental health care as well as to increase state and federal 
appropriations for community mental health to permit case management, more clinics, 
and more services for those who desperately need this assistance. 
   Second, the majority of funding for medication research comes from 
pharmaceutical companies. Many of the studies are completed in fulfillment of FDA 
requirements of trials required for protocols, with the goal of final drug approval for use 
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in the US.  These studies are usually 6 to 8 weeks, and rarely include the elderly 
population.  The newer drugs are also not included in the comparison studies.  Financial 
limitations drive the study designs, as the longer, RCT double blind placebo-controlled 
studies are more costly.  More funding must be allocated to independent researchers to 
encourage more, less biased studies to explore the full range of drugs available to the 
mental health population.   
Finally, in order to best meet the expanding need for mental health care in the US, 
PMH-NPs should be able to work within their full scope of practice. Removal of 
restrictions on practice in all states would provide a bounty of highly skilled professionals 
to care for the burgeoning older population, as well as the newly insured, to provide 
competent care for all.    Active participation in professional organizations at state and 
national levels, and taking leadership roles within the community and healthcare 
organizations, can help remove barriers to practice and raise awareness of the ways in 
which PMH-NPs can impact the healthcare system. 
Conclusion 
 The key points of this project will help psychiatric practitioners be successful in 
understanding the challenges and limitations of antipsychotic prescribing for older people 
with schizophrenia, and offers recommendations for medication management of patients 
who are living in the community.  The goal of treatment with antipsychotic medication is 
to achieve remission with fewer positive symptoms, reduced comorbid involvement, 
better self-esteem, and the ability to remain independent.  Dosage should be adjusted with 
the individual patient’s profile, preference, response, and history in mind.  By careful 
monitoring of the metabolic indices, and maintaining a dialogue with the patient’s 
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primary care provider or an independent practitioner, an active approach will minimize 
side effect potentials of comorbid complications.   
    Primarily, practitioners must understand that regarding antipsychotic 
medications, there is no right answer for what and how much to prescribe.  While the 
recommendations provided are a starting point, the best evidence to date involves 
utilization of the provider’s best judgment on a case-by-case basis. Understanding the 
patient as a person with unique preferences, personality, capabilities, and qualities is a 
prime component in this process, as important as expertise in medical treatment and 
psychopharmacology.  When reaching a clinical decision, practitioners can use guidelines 
but must generate a list of options based on best-practice choices distinct to each 
individual.  As new medication becomes available, the need for continuing education and 
reassessment of knowledge and assumptions remains an ongoing process for all mental 
health providers. 
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Appendix A 
Physiological Changes of Normal Aging by Body System 
Cardiovascular 
• A thickening of the interior lining of the heart muscle due to hypertrophy of 
muscle fibers and narrowing of blood vessels causing arteriosclerotic streaks 
and fibrous tissue to develop 
• Loss of contractile efficiency due to muscle fibers replacement with 
collagen or connective tissue calcium and decreased levels of circulating 
catecholamines 
• Decreased maximum heart rate and increased stroke volume with stress 
• Peripheral vascular resistance increased 1% per year after age 60   
• Cardiac output decreased one % a year 
• Failed valves in legs and varicose veins result in venous stasis 
• Higher blood pressure with longer time needed to return to baseline due to 
decreased diameter of arteries and diminished stretch ability 
• Decreased blood flow to the kidneys by 50% and 15-20% less to the brain 
Hematologic 
• Less sensitive baroreceptors 
• Decreased serum albumin concentration 
• Cell density of bone marrow decreased and cell proliferation diminished 
Respiratory 
• Loss of elasticity due to increased cross-linkage in collagen and elastin 
fibers around alveolar sacs, causing decreased vital capacity 
• Diminished chest wall compliance due to deformities of thorax, postural 
changes, decreased strength of muscular skeletal system to assist in 
respiration, degeneration of intervertebral disks, and increased anterior 
posterior diameter of the chest 
• Alveolar surface area collapse sooner on expiration, decreased by 20%, 
which reduces O2 uptake by as much as 60% at age 85 
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• Lung bases are less ventilated resulting in ineffective redistribution of blood 
to compensate 
 • Oxygen levels fall and become worse when lying down resulting in 
nocturnal hypoxemia (may cause confusion) 
• Decreased number of cilia with an increase of mucous producing cells 
• Less efficient in monitoring and controlling breathing  
• Less sensitive to hypoxia 
• History of smoking increased risks due to an increase in obstructive 
components of lung function and decreased compliance of lung tissue through 
deposits of foreign material 
Gastrointestinal:  Stomach 
• Shrinking and inflammation of the inner lining of the stomach from 
prolonged infection common in older adults 
• Insufficient production of stomach acid 
• Long-term use of pain medications causes stomach lining damage or H. 
pylori 
• Reduced colonic muscle tone and decreased colonic motor function 
• Degeneration of smooth muscle lining the lower two thirds of the esophagus 
resulting in delay in esophageal emptying, dilation of the esophagus, and 
increased nonproductive contractions 
• Oral issues include: loss of teeth, tongue papilla, reduced salivary ptyalin 
and reduced or irregular esophageal peristalsis contributing to poor intake, 
weight loss, and delayed emptying 
Gastrointestinal: Liver 
• Decreased ability of the liver to store Vitamin B12 
• Reduced size and blood flow, with restricted oxygen diffusion 
• Decreased ability to regenerate damaged liver cells 
Gastrointestinal: Intestines 
• Altered ability to absorb calcium, iron and lactose 
• Weakness of intestinal wall and impaired intestinal muscle function 
• Reduced peristalsis in the large intestine 
Urinary:  Renal  
• Kidney mass is decreased by 25-30% with a decrease by 30-40% in 
glomeruli by age 80, with an additional 30% sclerotic or nonfunctional  
• Decrease in creatine clearance 
• Total body water and lean body mass decrease 
• Difficulty maintaining acid/base balance 
• Hormones that regulate dehydration/hydration and the ability to conserve 
sodium decline  
• Decreased bladder capacity and residual urine 
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• Nocturnal frequency of micturition and urinary incontinence due to: loss of 
muscle tone that result in relaxation of perineal muscles (female); prostatic 
hypertrophy, bladder diverticula and sphincter relaxation (male) may increase 
UTI in both male and female 
• In the elderly: low fluid intake, fluid loss from diarrhea, vomiting, shock due 
to hemorrhage, acute or chronic cardiac failure, septicemia, toxicity from 
antibiotics or injudicious use of diuretics can lead to renal ischemia and acute 
renal failure 
 
Endocrine 
• Decreased insulin secretion and increased insulin resistance with decrease in 
insulin receptor sites in the cell walls (Normal FBS levels rise 6-14mg per 
deciliter every 10 yrs.) 
• Decrease in aldosterone (30%) by age 70-80  
• Cortisol decreased by 25% effecting anti-inflammatory and anti-allergy 
effects 
Neurological 
• Decline in homeostatic mechanisms 
• Intelligence remains unchanged 
• Nerve impulses decrease conduction rate by 10% with decreasing neurons 
and degenerating myelin sheath causing blurred signal and altered threshold 
of organ response after a stress response 
• Reduction in brain size by 20% with decrease in white matter by 11% 
between 70 to 90 yrs. old and decrease in the number of synapses 
• Decrease in dopamine content and receptor abundance   
• Brain loses 100 gm. resulting in reduced oxygen consumption, less 
intracellular energy produced, and glucose and cerebral blood flow reduced  
• Depression is associated with declining levels of norepinephrine  
• Declining dexterity and agility, difficulties with association, recall, and 
retrieval, with decreased memory and cognitive abilities 
•Decline in visual spatial abilities, both in perception and reproduction 
•Problem-solving skills decline after 70+ yrs. 
• Slowed processing reaction time 
Immune 
• Decreased production of thymic hormones 
• Decreased levels of antibody response 
• Diminished response to antigens 
Musculoskeletal 
• Loss of bone density: osteoblasts<osteoclasts 
• Loss of muscle mass with decrease in amount and size of muscle fibers 
(23% by age 80) 
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• Peripheral motor neurons: decreased protein synthesis with thickening at the 
myoneural junction and decreased acetylcholine level causing a general 
decreased in movement, muscle stiffness, and slowness in initiation of 
movement 
• Joint changes include: erosion of the cartilaginous surface, degenerative 
changes of soft tissue, calcification and ossification of ligaments, loss of 
cartilage elasticity, and development of fibroblasts  
• Increase in body fat 
 
Reproductive:  Female 
• Decrease by 95% of levels of circulating estrogen with menopause 
• Follicle stimulating hormone (FSH) and luteinizing hormone (LH) increase 
• Atrophic changes in uterus and vagina, thinning uterine lining, decreased 
elasticity and vaginal secretions with decreased libido and reduced or 
anorgasmic 
Reproductive:  Male 
• Decreased sperm production, by age 85,  a 35% reduction of testosterone 
and reduction in the size of the testes 
• Increased irregular thickening with fibrous tissue causes enlarged prostate 
• Decreasing testosterone levels may decrease libido, with a less intense 
orgasm to erectile dysfunction 
Sensory:  Vision 
• Corneal flattening reduces light admitted into the eye by one third. Pupil 
size decreases by one third 
• Transparency of the lens decreases with a yellowing occurs that alters colors 
(Blue become more green, reds and oranges become more vivid) 
• Diminished sensitivity of the retina reduces spatial discrimination, 
white/black contrast, and flicker sensitivity. More time required to adapt from 
dark to light 
• The lens becomes less elastic decreasing focus and reducing visual acuity 
• Arcussenilis may develop and lenses may cloud as a result of soluble 
proteins forming cataracts 
• Eyelids become thinner and wrinkled and skin folds from a loss of orbital fat 
leading to ptosis; inversion or eversions of the lids are common as the 
conjunctivae are thinner and more fragile 
 
Sensory:  Hearing 
• Reduction in auditory acuity with 10dB sensitivity loss for each decade 
beginning at age 60, male>female 
• Degeneration of the vestibular apparatus 
• Stiffness and less sensitive middle ear and tympanic membrane 
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• Reduction in hearing acuity of one-third the older population related to 
cerumen, antibiotics, or diuretics 
 
Sensory:  Olfactory, Taste, and Touch 
• Decrease in receptors beginning at age 50.  By age 80, smell reduced 50% 
• Atrophy of tongue and sensory receptors diminish taste 
• Decrease in touch receptors and response to painful stimuli 
 
 
Skin & Hair 
• Thinning of the area between the dermis and epidermis by two %, decrease 
in elastin and collagen with a reduction in the size of skin cells and a 
decreased ability to retain moisture 
• Thinning of the subcutaneous layer of fat under skin 
• Decrease in melanin and number of hair follicles with loss of pigment and 
slower growth 
• More facial hair with decreasing estrogen levels (female)  
• Increased hair growth in nose, ears, and eyebrows (male) 
• Less active sebaceous and sweat glands 
Note. Adapted from Pathophysiology: Adaptions and alterations in function (3rd ed.) by 
G. McDaniel, pp. 156-173.  Copyright 1992 by Courier Book Company. 
 
 
